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ABSTRACT 
Altered DNA methylation may lead to suboptimal fetal programming, increasing the risk 
of adverse pregnancy outcomes such as small for gestational age (SGA); however, few 
studies have examined the associations between DNA methylation, prenatal exposures, 
and fetal outcomes. Cross-sectional data from a larger, ongoing study were used to 
assess the impact of prenatal smoking on gene specific methylation of umbilical cord 
blood derived DNA and to investigate the association between gene-specific methylation 
and risk of SGA. The association between gene-specific DNA methylation and 
birthweight was also assessed. Maternal and infant covariates were abstracted from 
medical records, cigarette smoke exposure was determined by measuring cotinine in 
umbilical cord blood plasma, and the Illumina Infinium Methylation27 assay was used to 
assess CpG site specific methylation. Methylation was represented by a beta value 
ranging from 0 to 1. Gene-level methylation was calculated by averaging the methylation 
levels over the CpG sites interrogated in that gene. Logistic regression was used to 
generate adjusted odds ratios (OR) and 95% confidence intervals (CI) for the 
association between SGA and methylation of CYP1A1, HIF1A, GSTT1, and GSTM1 and 
the association between cotinine level and hypermethylation of CYP1A1, HIF1A, 
GSTT1, and GSTM1. DNA was considered hypermethylated if the beta value was 
greater than or equal to the 75th percentile. Univariate and multivariable linear regression 
were used to examine the association between birthweight and methylation of the IGF1 
and IGF2 gene. The analyses included 90 singleton births. A 0.10 unit increase in 
methylation of GSTT1 increased the risk of SGA almost 3-fold (OR=2.69, 95%CI=1.34, 
5.43). A 5ng/ml increase in cotinine level increased the risk of hypermethylation of 
vii 
 
GSTT1 (OR=1.18, 95%CI=1.02, 1.37). Birthweight did not appear to be impacted by 
methylation of IGF2 (β=0.07, 95%CI=-2.91, 3.05), but a one standard deviation increase 
in methylation of IGF1 was associated with a 3.63% decrease in birthweight (95%CI=     
-6.49, -0.78). No differences in DNA methylation by prenatal vitamin intake were 
detected. These findings suggest that DNA methylation plays a critical role in fetal 
growth and may mediate the risk of SGA and low birthweight. 
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CHAPTER ONE 
Introduction and theoretical framework 
Specific aims 
An increasing number of studies are linking prenatal exposures to adverse birth 
outcomes and adult onset disease. For example, heart disease, diabetes, and high 
blood pressure have all been associated with suboptimal pregnancy outcomes such as 
low birth weight and fetal growth restriction (1-4). Although it is posited that poor fetal 
growth is an in utero survival mechanism that enables the fetus to adapt to its 
environment, the mechanism underlying these adaptations are still poorly described.  
Epigenetic modifications, heritable changes in gene expression that are not 
accompanied by changes in genotype, such as DNA methylation, have not been largely 
explored as potential mechanisms by which suboptimal uterine conditions leads to poor 
fetal growth in humans (5). Nonetheless, experimental evidence has demonstrated that 
DNA methylation is critical to normal development of mammals and that abnormal 
methylation can result in diseases such as Rett syndrome, neoplasias, and facial 
abnormalities (5-7). Accordingly, several genes critical for fetal and postnatal growth are 
epigenetically regulated (8-11). Furthermore, DNA methylation appears to be directly 
altered by exposures such as cigarette smoke and folic acid (12-15). Although aberrant 
DNA methylation has been linked to cigarette smoke, folic acid, and other potential in 
utero exposures, less is known about the association between DNA methylation and 
birth outcomes. Normal methylation of DNA, a process that is important for regulation of 
gene expression and DNA stability, may be disrupted in response to suboptimal uterine 
conditions, altering gene expression and subsequently preventing normal growth.  
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Given the lack of information about fetal exposures, DNA methylation, and 
pregnancy outcomes, this study sought to examine the association between DNA 
methylation of specific genes and indicators of fetal growth (small for gestational age 
and birthweight). In addition, it examined the impact of prenatal smoking on DNA 
methylation. Consequently, the analysis centered on the methylation of genes related to 
the metabolism of cigarette smoke carcinogens and genes important for fetal growth. 
The central hypothesis of this study is that suboptimal uterine conditions during 
pregnancy results in aberrant DNA methylation in umbilical cord blood-derived nucleated 
cells, which manifests itself as impaired fetal growth. The hypothesis is tested in a cross-
sectional study including 92 infants recruited from a larger, on-going study at Tampa 
General Hospital (TGH). The study will help elucidate the biological mechanism by which 
cigarette smoke exerts its negative effects and, importantly, the role of gene-specific 
DNA methylation in mediating fetal growth.  
The specific aims of this study include: 
1. To investigate the association between small for gestational age (SGA) and 
the degree of DNA methylation in genes involved in xenobiotic metabolism 
and hypoxic response, specifically hypoxia inducible factor 1, cytochrome 
P450, glutathione s-transferase (GST) M1, and GSTT1  
2. To determine if there is a dose-response relationship between DNA 
methylation of selected xenobiotic metabolism and hypoxic response genes 
and risk of SGA  
3. To determine whether cigarette smoke exposure is associated with altered 
methylation levels in genes involved in metabolism of xenobiotics and 
hypoxic response 
4. To determine whether suboptimal methylation of the Insulin-like growth factor 
(IGF) genes, IGF1 and IGF2 are associated with infant birthweight 
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Fetal growth and birthweight 
Birthweight and intrauterine growth restriction (IUGR) are frequently used as 
indicators of fetal growth and survival potential. IUGR occurs when infants or fetuses fail 
to meet their growth potential and is typically operationalized based on birthweight and 
its appropriateness for a given race and gestational age (16, 17). Under this 
classification scheme, infants weighing less than the 10th percentile for a given 
gestational age, race and gender are considered small for gestational age (SGA), those 
above the 90th percentile are large for gestational age (LGA), and the remainder are 
appropriate for gestational age (AGA) (16). The percentage of SGA infants born in the 
United States ranges from 7.87% for non-Hispanic whites to 15.43% for non-Hispanic 
blacks (16). Hispanics have an intermediate rate of 9.30% (16). IUGR can also be 
categorized as symmetrical (proportional reductions in weight, length, and head 
circumference) or asymmetrical (reductions in weight are markedly higher than 
reductions in length or head circumference) (18, 19). Symmetrical growth restriction is 
characterized by smaller head dimensions and abdominal size that usually results from 
insults that occur early in gestation (birth defects, chromosomal anomalies, smoking, 
etc.) when growth occurs by cell division (17, 20). Asymmetrical growth restriction is 
marked by normal head dimensions and decreased abdominal size (17, 19). 
Asymmetrical growth restriction usually occurs in response to placental factors, diabetes 
mellitus, or inadequate nutrition in late pregnancy when cells are increasing in size (17, 
20).   
On the other hand, birthweight is reflective of fetal growth throughout the 
pregnancy. Birthweight is a product of gestational age and fetal growth, thus low 
birthweight, a common pregnancy outcome measure, can be attributed to poor fetal 
growth or preterm birth. Birthweight is frequently categorized as low birthweight (less 
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than 2500 grams), normal birthweight (2500 grams-4000 grams), or macrosomic (>4000 
grams) (21).  Birthweight is one of the best predictors of infant mortality, although the 
association may not be causal (22). The mean birthweight of singleton infants is 3,325 
grams with about 6.2% of singleton infants and 7.9% of all infants being born low 
birthweight (21). However, the rates of low birthweight differ by race and ethnicity with 
non-Hispanic blacks having the highest rates (13.6%) followed by non-Hispanic whites 
(7.0%) and Hispanics (6.2%) (21). Birthweight has a very low heritability, thus it is 
thought that environmental factors play a critical role in birthweight determination (23).  
The mechanism by which poor fetal growth manifests in response to 
environmental factors is unclear, but it may also depend on maternal morbidity and 
nutrition (16). Growth is dependent on adequate nutrition, oxygen, and hormones and 
growth factors, and suboptimal uterine conditions may impair availability of these factors, 
possibly by altering gene expression. Epigenetic modifications are a reversible 
mechanism that could account for the alterations in gene expression, and the ability of 
some fetuses to circumvent adverse outcomes attributed to adverse uterine 
environments. 
 
Exposures associated with fetal growth 
Maternal smoking  
 In the United States, about 21% of reproductive aged women smoke, and about 
12% of women continue to smoke during pregnancy (24, 25). An even greater proportion 
of women are exposed to environmental tobacco smoke (33%) (26). Numerous large 
epidemiologic studies have provided evidence linking prenatal tobacco smoke exposure 
to a number of poor birth outcomes, including IUGR, stillbirth, and low birthweight, and 
now the relationship between IUGR and prenatal tobacco smoke exposure is presumed 
to be causal (27).  
5 
 
Reduced fetal growth attributed to prenatal tobacco smoke exposure may be due 
to nicotine exposure itself, hypoxia, placental changes, or direct effects of other 
chemicals, but the exact mechanism remains unknown. Nicotine, a known 
vasoconstrictor, can cross the placenta, exposing the developing fetus to higher nicotine 
concentrations than the mother (28, 29). The vasoconstrictive effect of nicotine may 
decrease the transfer of nutrients across the placenta and cause hypoxia, impairing 
normal processes of fetal growth and development (30). Conversely, animal studies 
suggest that carbon monoxide, not nicotine or other chemical exposures is responsible 
for the observed decreases in birth weight in fetuses prenatally exposed to tobacco 
smoke (31). High carbon monoxide concentrations can cause hypoxia, resulting in 
altered trophoblast expression, which are important for placental transfer, hormone 
production, and metabolism (32, 33).   
Morphological changes in the placentas of smokers have been documented, but 
these changes have not been found to be associated with growth restriction (34). 
Placentas of smokers have thickened villous membranes, reduced capillary volumes, 
and decreased weight, but oxygen diffusion, a factor that may limit growth, does not 
seem to be impaired (34-36)  Transfer of folate across the placenta may also be 
impaired by placental changes, a problem compounded by observations indicating that 
smokers have lower serum folate levels than nonsmokers (37). Studies examining 
maternal-fetal folate transfer in smokers and nonsmokers have not supported this 
hypothesis. Jauniaux et al. reported folate levels inside the first trimester gestational sac 
as measured in coelomic fluid did not differ between smokers and nonsmokers, but they 
were lower than those found in maternal serum, suggesting that smoking does not 
impair placental transfer of folate (37).  
Several studies have examined the anthropometric measurements of infants 
born to smokers and nonsmokers, noting that tobacco smoke exposure usually causes 
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symmetrical growth restriction (38, 39).  Higgins et al. demonstrated that maternal 
smoking decreases birth weight, crown-heel length, head circumference, and reduces 
brain:body weight ratio (BRR) (40). The same study reported that smoking cessation 
before 32 weeks’ gestation eliminated the reductions in birth weight and head 
circumference, but deficits in crown-heel length, BRR, and ponderal index remained 
(40).  Other studies have also linked prenatal smoking to reductions in linear growth, 
femur length, head circumference, and abdominal circumference  (41-43). Numerous 
studies have demonstrated a dose-response inverse relationship between number of 
cigarettes smoked and birthweight (42, 44). In addition, fetal growth restriction correlates 
with nicotine concentration in fetal blood in a dose-response pattern (45). Both term and 
preterm infants are affected by maternal smoking (42).  
Maternal smoking is associated with lower concentrations of amino acids in 
umbilical cord blood plasma and altered activity of trophoblasts and enzymatic activity 
(34, 46).  Conversely, studies have shown that there are no differences in triglyceride, 
glucose, or albumin concentrations in umbilical cord blood between infants exposed to 
cigarette smoke prenatally and their unexposed counterparts (39). When compared to 
infants of nonsmokers, those born to smokers have lower insulin-like growth factor and 
IGF binding protein 3 in umbilical cord blood (39). In addition, smokers tend to gain less 
weight during pregnancy, but this does not explain the decreases in fetal size as an 
increase in nutrient intake does not prevent poor fetal growth in infants exposed to 
tobacco smoke prenatally (47, 48).  
 
Folate 
Folate is a water soluble B vitamin that plays a critical role in human reproduction 
(49). It occurs naturally in leafy green vegetables, beans, and liver, but it also exists in 
synthetic forms. Folic acid (naturally occurring or synthetic folate) is an important 
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substrate in one carbon metabolism, purine and amino acid synthesis, and methylation 
reactions (50-53). Folate is an essential component in reactions proceeding RNA and 
DNA synthesis which highlights the significance of folic acid for fetal growth and 
development (54).  
Food fortification is one method that can help ensure adequate folic acid intake 
during the periconceptional period (55, 56). In 1998, the United States (US) Food and 
Drug Administration (FDA) began fortifying staple foods, including flour, rice, cereal, and 
pasta, with approximately 10% of the recommended daily intake (RDI) of folic acid 
(400µg) in an effort to increase folic acid intake (57, 58). Although successful, many 
reproductive aged women (aged 15-44) still do not have adequate folate intake (59). 
Non-Hispanic white women have the highest intake and the greatest proportion of 
women meeting the RDI (30.3%), followed by Mexican-Americans (17.1%) and non-
Hispanic blacks (9.1%) (59). Dietary supplements including prenatal vitamins and other 
vitamins are an important source of folic acid for reproductive aged women. Women who 
took supplements containing folic acid were more than 10 times more likely to meet the 
RDI than non-users (95%CI=7.1, 14.7) (59). 
The success of folate supplementation in decreasing the incidence of neural tube 
defects has lead to the investigation of the impact of folate on other fetal outcomes, such 
as low birthweight and IUGR (49). A large meta-analysis reported a decreased risk of 
low birthweight among infants born to women who used multimicronutrients (OR=0.81, 
95%CI=0.73, 0.91) or iron-folic acid supplements (OR=0.83, 95%CI=0.74, 0.93) as 
compared to placebo, but there was no difference in risk for SGA (60). Similarly, 
Neggers et al found that folate supplementation increased birthweight by 48 grams (61). 
In addition, the Generation R Study found that periconceptional folic acid use increases 
birthweight by 68 grams (95%CI=37.2, 99.0 grams) (62). The same study also reported 
a reduced risk of SGA (OR=0.40, 95%CI=0.22, 0.72) (62). Although some studies 
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reported conflicting results, the importance of folic acid in one carbon metabolism 
support the observed associations and additional studies examining the mechanism 
underlying the association between folic acid and fetal growth are warranted (50-53, 63). 
 
Biological mechanism linking exposures to birth outcomes and DNA methylation 
Epigenetics and DNA methylation 
Gene expression is mediated not only by DNA sequence, but also by epigenetic 
factors. Epigenetic modifications encompass three main processes: (1) DNA 
methylation; (2) histone acetylation; (3) micro-RNA molecules.  Epigenetic modifications 
such as DNA methylation have been shown to affect disease susceptibility in human and 
animal studies as it regulates gene expression (5-7). DNA methylation occurs primarily 
at cytosine dinucleotides in the sequence cytosines and guanine (CpG) (64, 65). In most 
of the DNA sequence, CpG dinucleotides occur infrequently and a majority (~80%) are 
methylated. Alternatively, there are regions of DNA sequence that are very rich in CpG 
dinucleotides, termed CpG islands which primarily occur in gene promoter regions. 
Interestingly, during active gene transcription (open chromatin structure), CpG islands 
are unmethylated (64, 65). About 60% of genes have a CpG island at the 5’ end of the 
promoter region which are important for transcriptional regulation (50, 52, 64). 
Expression of the promoter associated with a given CpG island is not dependent on 
methylation status (i.e. it may not be expressed even though it is not methylated), but 
methylation silences the promoter by promoting histone de-acetylation and a closed 
chromatin structure (64). Similar activity is seen in X-chromosome inactivation and 
imprinting (64). Consequently, disease can often be ascribed to failure to maintain 
normal DNA methylation, an epigenetic marker that can be assessed globally or at 
specific gene sites. 
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In normal fetal development, there is a wave of demethylation after fertilization 
that affects all methylated regions except the imprinted loci (66, 67). DNA methylation 
patterns are restored as development continues. De novo genome wide methylation 
occurs between formation of the blastocyst and gastrulation and then as cells 
differentiate, changes in gene-specific methylation occur (66).  Imprinting occurs prior to 
fertilization and acts to silence either the maternal or paternal allele so that there is 
monoallelic expression of imprinted genes (66, 68).Disruption of normal imprinting is 
associated with several different syndromes, such as Beckwith Weidemann syndrome 
(66, 69). 
DNA methylation requires S-adenosylmethionine (SAM), thus nutritional 
manipulation of the factors that are involved in the synthesis of SAM could impact DNA 
methylation reactions (50-52). However, SAM can be derived from a number of different 
dietary factors via different metabolic pathways and disruptions in one factor results in 
compensatory changes in other metabolic pathways (50, 51, 70). Figure 1.1 provides a 
schematic of some of the substrates and reactions that are involved in DNA methylation. 
Complex metabolic pathways involved in the methylation cycle may explain some 
authors’ findings. Maloney et al. found that in rats, folate deficient diet intake during 
pregnancy did not impact DNA methylation in offspring (71). The authors did observe 
metabolic alterations, suggesting that alternative pathways were used to prevent 
aberrant methylation. Conversely, studies that looked at folate supplementation as 
opposed to folate deficiencies found an increase in DNA methylation, suggesting that 
diets deficient in methyl donors, such as folate do not directly influence the methylation 
of DNA, but diets rich in methylating factors can restore normal methylation (15, 52). 
Other studies have reported hypomethylated DNA in animals fed diets deficient in 
choline and methonine  (50).  
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 Maternal supplementation with methyl donors (ie; SAM, folic acid, choline, etc.) 
may be able to compensate for the negative effects of adverse intrauterine 
environmental exposures that impact DNA methylation. Dolinoy et al (2007) 
demonstrated that dietary supplementation of folic acid can prevent CpG site specific 
DNA hypomethylation caused by exposure to bisphenol A (BPA), a chemical used in the 
manufacturing of certain plastics (14). Restoration of normal methylation patterns 
prevents incorrect programming and could preclude subsequent diseases such as 
increased body weight, cancer and poor reproductive function (14). Similar results have 
been observed in animal studies (15, 72). Lillycrop et al. demonstrated that the offspring 
of rats fed protein-restricted diets had hypomethylated DNA in the glucocorticoid 
receptor and that supplementation with folic acid could prevent hypomethylation of the 
glucocorticoid receptor (15). Therefore, it seems that while high folate diets can prevent 
gene specific DNA hypomethylation, low folate diets do not necessary cause DNA 
hypomethylation, but it does cause changes in metabolism that may induce alterations in 
methylation (71).  
Genetic alterations may also impact DNA methylation, such as single nucleotide 
polymorphisms (SNPs), especially when SNPs occur within genes that are integrally 
linked to the methylation cycle. Methionine synthase reductase, MTHFR, and methionine 
synthase are enzymes that have common polymorphisms and the latter two are 
influenced by folate deficiencies (51). Associations between these polymorphisms and 
diseases such as cancer, birth defects, and cardiovascular disease have been identified. 
However, their role in DNA methylation is not entirely clear as it may be modulated by 
gene polymorphisms as well as interactions between numerous dietary methyl donors 
(51, 73).  
Alterations in DNA methylation may be the mechanism by which smoking causes 
poor fetal growth as methylation affects gene expression and in turn enzymatic activity 
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important for normal growth. Recent studies have found that several imprinted genes 
(genes that are turned on or off permanently via DNA methylation, histone acetylation, or 
chromatin modification) play a critical role in placental growth and nutrient transfer (33, 
74). Furthermore, maternally expressed genes suppress fetal growth whereas paternally 
expressed genes enhance it, thus errors in imprinting can have various affects (68, 74). 
Environmental factors, such as smoking can have detrimental effects on methylation and 
thus gene imprinting; therefore, a better understanding of the smoking-induced changes 
in methylation may further delineate the mechanism by which prenatal smoke exposure 
causes IUGR (12, 74). Nonetheless, conflicting evidence has left the exact mechanism 
by which smoking exerts its negative effects elusive and to date, smoking cessation is 
the only strategy that is known to prevent IUGR and low birthweight. 
 
Epigenetics, smoking, and birth outcomes 
While DNA methylation has not been largely studied in relation to smoking during 
human pregnancies, it has been investigated in animal studies and studies of cancer. 
Reports of smoking-related cancers have demonstrated that tobacco smoke exposure 
may impact global and CpG site specific DNA methylation (12, 75). Consistent with 
these results, a study of bladder cancer cases suggests that cases had decreased DNA 
methylation and that tobacco smoke exposure modified the association between global 
DNA methylation and disease (13). The risk of bladder cancer was highest among 
current smokers with the highest levels of global DNA methylation (13). Interestingly, the 
study noted that global DNA methylation was not associated with genetic polymorphisms 
in 1-carbon metabolism such as MTHFR (13). Associations between global DNA 
methylation and smoking have been reported in other studies and some noted 
correlations between MTHFR and methylation only under conditions of low folate (76).  
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Methylation changes in specific genes may mediate fetal response to uterine 
conditions ultimately impacting fetal growth. Several genes that are involved in fetal 
response to hypoxia and cigarette smoke exposure may also mediate IUGR risk. 
Glutathione S-transferases (GST) metabolize environmental pollutants such as 
insecticides and carcinogens as well as by-products of oxidative stress (77). GSTM1 is a 
major phase 2 enzyme that catalyzes the conversion of phase one metabolites into 
glutathione and impaired enzyme activity may alter the response to cigarette smoke 
sand other toxicants (77-79). Hypermethylation of GSTM1 or GSTT1 may decrease the 
ability to metabolize xenobiotics, prolonging exposure and increase the risk of IUGR. 
The cytochrome (CYP) P450 enzymes and GSTT1 are also important for the 
metabolism of polyaromatic hydrocarbons (PAHs). Previous studies suggest that altered 
expression of genes involved in xenobiotic metabolism may increase the risk of IUGR 
(79-81). Further, cancer studies suggest that expression of some of the CYP450 
enzymes are down regulated by promoter hypermethylation and abnormal methylation is 
associated with some cancers (82). Hypoxia inducible factor 1 (HIF-1) also modulates 
gene expression in response to hypoxia and recent evidence indicates that it is mediated 
by methylation whereby hypermethylation decreases transcription (83, 84). A summary 
of the genes described above is provided in Table 1.1. 
Follow-up data from the National Collaborative Perinatal Project examined DNA 
methylation in relation to exposures that occurred throughout the life course and 
reported an association between prenatal smoke exposure and higher levels of global 
DNA methylation in peripheral blood mononuclear cells; however, prenatal smoke 
exposure was based on maternal self-report (85). Additional studies are needed to 
examine the impact of prenatal smoking on gene-specific methylation as this may impact 
gene expression and subsequent fetal growth. 
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Epigenetics, folate, and birth outcomes 
Both IUGR and low birthweight manifest in response to a number of different 
causes, including birth defects and other chromosomal anomalies, multiple gestation, 
high altitude, extreme malnutrition, dietary deficiencies, abnormal placenta, or maternal 
smoking (17, 86, 87). Most studies examining folic acid and prenatal vitamin use focused 
on prevention of birth defects, but DNA methylation is one possible mechanism by which 
folic acid may mediate fetal growth.  
Folic acid deficiency may prevent normal methylation of epigenetically regulated 
genes such as insulin-like growth factor (IGF) 1 and IGF2.  In addition to IGF1 and IGF2, 
the IGF system also includes insulin, four receptors, and six binding proteins (88). It 
regulates fetal and placental growth, promoting cell growth and differentiation and 
inhibiting apoptosis (8, 9). Both IGF1 and IGF2 are expressed early in fetal development, 
however IGF2 expression exceeds that of IGF1 (88). IGF2 is a paternally imprinted gene 
and since expression is regulated by DNA methylation, it may vulnerable to abnormal 
methylation during development. Although imprinting can be detected as early as the 8-
cell stage, after birth, IGF2 expression becomes biallelic in most tissues (88, 89). 
Imprinting of IGF2 is regulated by H19, but loss of imprinting of IGF2 can occur 
regardless of whether imprinting is disrupted in H19 (90). The importance of methylation 
in the expression of IGF2 is underscored by the fact that fetal overgrowth is associated 
with imprinting disorders such as Beckwith-Wiedemann syndrome (69, 91). Knockout 
studies of IGF1 or IGF2 decreases fetal weight in mice and partial deletion of IGF1 in 
humans has similar effects (8, 11). For example, in mice, deletion of IGF2 results in a 
fetus that is only 60% of the normal weight (8, 92).  
Although epigenetic control of IGF1 has received less attention, animal studies 
suggest that IGF1 methylation is altered in intrauterine growth restricted (IUGR) rats and 
that hypermethylation decreases IGF1 expression (93).  IGF1 and birthweight are 
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positively associated and growth restricted infants have low umbilical cord blood levels 
of IGF1 compared to their counterparts with normal growth (11, 93, 94). Infant sex and 
concentrations of IGF1 and IGF binding protein 3 in umbilical cord blood plasma explain 
about 38% of the variability in birthweight after adjusting for gestational age, parity and 
maternal height (95). Together, these findings suggest that IGF1 and IGF2 are critical 
drivers of fetal growth and that sub-optimal methylation may impair fetal growth (see 
Table 1.2).  
Although the mechanism by which folic acid impacts fetal growth and 
development, its universal methyl-donor status, may enable it to help prevent sub-
optimal methylation of genes critical for fetal growth. Findings of recent studies such as 
that of Steegers-Theunissen et al support this theory as they reported that infants 
exposed perinatally to folic acid had higher methylation of the IGF2 DMR (differentially 
methylated region) than their unexposed counterparts (10). In addition, a methylation 
increase of 1.7% in the IGF2 DMR was associated with increased birthweight (10). 
However, it is possible that the time of sampling (about 17 months after delivery) 
impacted methylation of IGF2 as IGF2 expression changes after birth (8, 10, 88). 
Similarly, prenatal exposure to famine has also been associated with decreased 
methylation of IGF2 (96). Few studies have evaluated the impact of methylation of IGF1 
or IGF2 on fetal growth in humans and additional studies are needed to explore the 
possible associations. 
 
Summary 
 An increasing number of studies suggest that DNA methylation is a critical 
component of fetal development, yet it has not been largely explored as potential 
mechanism by which suboptimal uterine conditions leads to poor fetal growth in humans  
(5).  This study seeks to address the lack of information by examining the relationship 
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between DNA methylation of genes involved in xenobiotic metabolism and 1) 
biochemically validated prenatal cigarette smoke exposure and 2) risk of SGA. This 
information may help elucidate the biological mechanism by which cigarette smoke 
exposure causes adverse pregnancy outcomes. In addition, this study examines the 
relationships between DNA methylation of IGF1 and IGF2, prenatal vitamin use, and 
birthweight. Previous studies have reported conflicting evidence for the association 
between birthweight and prenatal vitamin use, but few have examined this association in 
relation to a biological mechanism (54, 61, 63). Understanding the mechanisms by which 
adverse pregnancy outcomes manifest may lead to enhanced prevention strategies to 
reduce the morbidity and mortality associated with adverse pregnancy outcomes such 
as SGA and low birthweight. 
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Table 1.1 Overview of CYP1A1, HIF1A, GSTM1, and GSTT1 as they relate to fetal 
growth, DNA methylation, and response to prenatal cigarette smoke exposure 
Gene Description/function Literature overview References 
CYP1A1  Phase 1 enzyme 
 Important for 
detoxification and 
metabolism of 
xenobiotics 
 Involved in metabolic 
activation of PAHs 
from tobacco smoke 
 Expression of CYP1A1 associated 
with cigarette smoke exposure 
 cancer studies suggest that 
expression of some of the CYP450 
enzymes are down regulated by 
promoter hypermethylation and 
abnormal methylation is associated 
with some cancers  
 Placental CYP1A1 upregulated in rat 
model of smoking induced IUGR 
 Excess PAHs may lead to DNA 
adducts  
(80-82, 97) 
HIF1A  Modulates gene 
expression in 
response to hypoxia  
 Tightly regulated by 
oxygen 
concentration and 
determines the level 
of HIF1 activity  
 
 HIF1a expression is critical for 
downstream activation of a number of 
genes involved in cell growth and 
viability as well as in vascularization, 
factors critical for normal fetal growth 
 It has been shown that the 
expression of HIF1a is epigenetically 
regulated and DNA methylation 
suppresses expression in some cell 
types 
 Abnormal methylation of HIF1a may 
suppress HIF1a and lead to fetal 
growth inhibition. 
(83, 84, 98, 
99) 
GSTT1 
and 
GSTM1 
 2 types of 
glutathione S-
transferases 
 Phase 2 enzymes 
involved in 
detoxification of 
phase 1 metabolites 
into compounds that 
can be easily 
excreted  
 Act on a wide range 
of epoxides, 
hyperperoxides, and 
other substrates 
 Metabolize environmental pollutants 
such as insecticides and carcinogens 
as well as by-products of oxidative 
stress  
 Enzymes involved in the metabolism 
of cigarette smoke and polyaromatic 
hydrocarbons (PAHs), thus impaired 
enzymatic activity may alter 
detoxification ability 
 Loss of expression of these genes 
may impair clearance of PAHs or 
their metabolic by-products, 
interfering with DNA transcription and 
replication, or impairment of  
trophoblast proliferation, all of which 
may increase the risk of IUGR 
 
(77-79) 
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Table 1.2 Summary of IGF1 and IGF2  
 
Gene Description/function Literature overview References 
IGF1  Regulates fetal and 
placental growth, 
promoting cell 
growth and 
differentiation and 
inhibiting apoptosis 
 Knockout studies of IGF1 
decreases fetal weight in mice 
and partial deletion of IGF1 in 
humans has similar effects 
 Animal studies suggest that IGF1 
methylation is altered in 
intrauterine growth restricted 
(IUGR) rats and that 
hypermethylation decreases IGF1 
expression  
 IGF1 and birthweight are 
positively associated and growth 
restricted infants have low 
umbilical cord blood levels of 
IGF1 compared to their 
counterparts with normal growth  
 Infant sex and concentrations of 
IGF1 and IGF binding protein 3 in 
umbilical cord blood plasma 
explain about 38% of the 
variability in birthweight after 
adjusting for gestational age, 
parity and maternal height  
(11, 93-95) 
IGF2  Regulates fetal and 
placental growth, 
promoting cell 
growth and 
differentiation and 
inhibiting apoptosis 
 Paternally imprinted 
gene 
 Expression is 
greater than that of 
IGF1 
 After birth, IGF2 
expression 
becomes biallelic in 
most tissues  
 Knockout studies of IGF2 
decreases fetal weight in mice 
 Findings of recent studies 
reported that infants exposed 
perinatally to folic acid had higher 
methylation of the IGF2 DMR 
(differentially methylated region) 
than their unexposed 
counterparts.  
 A methylation increase of 1.7% in 
the IGF2 DMR was associated 
with increased birthweight  
 Prenatal exposure to famine has 
also been associated with 
decreased methylation of IGF2 
(10, 88, 89, 
96) 
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Figure 1.1 Schematic of some of the substrates (folate, choline, methionine) and 
reactions involved in the methylation of DNA (52, 73) 
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CHAPTER TWO 
Manuscript 1: The association between fetal growth restriction, cotinine, and DNA 
methylation of detoxification and hypoxia related genes 
 
Abstract 
Objective: We assessed the impact of prenatal smoking on DNA methylation and the 
association between methylation and risk of small for gestational age (SGA).  
 
Methods: Medical record data and biological samples from 90 singleton births were 
obtained from an ongoing, cross-sectional study. Cigarette smoke exposure was 
determined by measuring cotinine in plasma and CpG site-specific methylation in DNA 
extracted from umbilical cord blood was measured with the Illumina Infinium 
Methylation27 assay. Gene-level methylation was calculated by averaging the 
methylation levels over the CpG sites interrogated in that gene. Maternal and infant 
characteristics were compared by SGA status as well as by hypermethylation status 
using fisher’s exact test and t-tests as appropriate. Logistic regression was used to 
generate adjusted odds ratios (OR) and 95% confidence intervals (CI) for the 
association between SGA and methylation of CYP1A1, HIF1A, GSTT1, and GSTM1 and 
the association between cotinine level and hypermethylation of the aforementioned 
genes.  
 
Results: SGA infants were less likely to have adequate prenatal care and were more 
likely to be black and female. Infants with hypermethylation of GSTT1 were more likely 
to be black. A 0.10 unit increase in methylation of GSTT1 increased the risk of SGA 
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almost 3-fold (OR=2.69, 95%CI=1.34, 5.43) and the association appeared to be dose-
dependent (p<0.001). The risk of hypermethylation of GSTT1 increased with increasing 
cotinine level (5ng/ml increase: OR=1.18, 95%CI=1.02, 1.37; 20ng/ml increase: 
OR=1.94, 95%CI=1.06, 3.53).  
 
Conclusion: Methylation appears to play a critical role in fetal response to cigarette 
smoke and may influence the risk of SGA. 
 
Introduction 
Intrauterine growth restriction (IUGR) is a significant contributor to infant 
morbidity and mortality, thus its prevention has important public health implications (17, 
100). The spectrum of evidence suggests that the relationship between prenatal 
smoking and IUGR is causal (27, 41, 101, 102). However, the mechanism by which 
prenatal tobacco smoke exposure causes adverse pregnancy outcomes remains poorly 
defined. Studies suggest a number of different modes of action, including 
vasoconstriction of the placenta, hypoxia, inhibited amino acid transport, and disrupted 
lipid metabolism (30, 103, 104).  Although each of these mechanisms is biologically 
plausible and has supporting evidence, none has been able to explain why some 
fetuses, although exposed to tobacco smoke, are not growth restricted. 
Previous studies have identified a number of genes involved in xenobiotic 
metabolism and these genes may mediate IUGR risk (79, 105). Glutathione S-
transferases (GST) metabolize environmental pollutants such as insecticides and 
carcinogens as well as by-products of oxidative stress (77). GSTM1 is one of the 
enzymes involved in the metabolism of cigarette smoke and polyaromatic hydrocarbons 
(PAHs), thus impaired enzymatic activity may alter detoxification ability (77-79). 
Similarly, GSTT1 and the cytochrome (CYP) P450 enzymes are important for the 
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metabolism of PAHs and loss of expression of these genes may impair clearance of 
PAHs or their metabolic by-products, interfering with DNA transcription and replication, 
or impairment of  trophoblast proliferation, all of which may increase the risk of IUGR 
(79, 80, 106, 107). Further, expression of some of the CYP450 enzymes is mediated by 
promoter methylation, with aberrant methylation occurring in some colorectal cancers, 
suggesting that changes in methylation may impact disease risk (82). In addition, 
hypoxia inducible factor 1 (HIF-1) modulates gene expression in response to hypoxia 
and recent evidence indicates that it is silenced by DNA methylation (83, 84).  
Studies have shown that DNA methylation can be directly altered by exposure to 
cigarette smoke (12, 13). Recent studies have also found that in utero tobacco smoke 
exposure changes global and gene-specific methylation profiles in young children (108). 
However, the exposure and methylation changes in the aforementioned study were 
assessed about 5 to 6 years apart, thus, it is possible that postnatal exposures resulted 
in the observed DNA methylation changes (108). Other studies examining detrimental 
prenatal exposures also suggest that they may alter DNA methylation. For example, 
Pilsner et al found that maternal tibia lead burden was negatively associated with 
methylation of umbilical cord genomic DNA (109). Together, these observations suggest 
that epigenetic modifications, such as DNA methylation, may be a potential mechanism 
by which suboptimal uterine conditions caused by tobacco smoke exposure leads to 
IUGR, yet this potential pathway remains insufficiently explored. To examine this 
mechanism as a potential pathway, we undertake this study with the following 
hypotheses: 1) suboptimal uterine conditions may prevent normal fetal programming 
through altered DNA methylation of CYP1A1, HIF1A, GSTM1, and GSTT1, an event that 
is subsequently displayed phenotypically as SGA; 2) that there is a dose-response 
relationship between gene specific DNA methylation in DNA isolated from mononuclear 
cells and risk of SGA whereby infants with the highest methylation levels have the 
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highest risk of SGA; and 3) that cigarette smoke exposure is associated with altered 
methylation levels in genes involved in metabolism of xenobiotics. 
 
Methods 
Study sample and data collection 
All study participants in this cross-sectional study were enrolled at Tampa 
General Hospital in Tampa, Florida as part of a larger ongoing study examining 
lymphocyte subpopulations and prematurity. All pregnant females delivering at Tampa 
General Hospital were eligible to participate in the Lymphocyte Study. However, infants 
born to women whose prenatal tests indicated that they were HIV positive or Hepatitis B 
positive were excluded. Maternal race and ethnicity are not factors for inclusion. For the 
present study, infants with birth defects were excluded and only singleton infants were 
eligible for inclusion. 
De-identified demographic and clinical variables initially collected via medical 
record abstraction using standardized forms as part of the parent study were also 
obtained. The data elements collected include: gestational age, infant birth weight, infant 
sex, presence of infection, delivery complications, presence of birth defects, plurality, 
parity, gravidity, prenatal care usage, maternal age, and race.  
 
Umbilical cord blood collection 
In addition to medical record data, the Lymphocyte Study also collected umbilical 
cord blood samples. The umbilical cord blood samples were collected by venipuncture of 
the umbilical cord after delivery of the placenta into tubes containing EDTA and were 
processed within 24 hours of collection. Samples were processed at the University of 
South Florida. Plasma was removed and stored in 1ml tubes at -80°C for subsequent 
cotinine analysis. A ficoll gradient separation was used to isolate the mononuclear layer. 
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The amount of cord blood processed varied as the amount collected differed for each 
infant. However, it ranged from 0.5ml to 5.5ml. After separation, samples were 
suspended in freeze media (fetal bovine serum and 10% DMSO) and stored in liquid 
nitrogen. Studies have demonstrated that long term storage of cryopreserved cells does 
not impact cell viability or recovery with greater than 80% of nucleated cells recovered 
(110).  
 
DNA isolation and DNA methylation assessment  
DNA isolation and methylation assessment was done at Wayne State University 
Applied Genomics Technology Center. Laboratory personnel were blinded to birth 
outcome and other maternal and infant health indicators. DNA was isolated from the 
mononuclear fraction of umbilical cord blood using the Qiagen EZ1 DNA tissue kit 
according to Lum et al with the exception that PBS (phosphate buffered saline) was 
substituted for TE (tris ethylenediaminetetraacetic acid) buffer (111). The mononuclear 
fraction is largely comprised of monocytes and lymphocytes, but also contains 
hematopoietic stem cells (112).  Changes in cells derived from umbilical cord blood 
should more directly reflect changes that occurred in relation to suboptimal fetal 
environment, leading to IUGR. After extraction, DNA was quantified by loading 3µl of the 
DNA suspension in the Trinean Dropsense96. 
Bisulfite modification of 0.5 µg of DNA was then done with the EZ-96 DNA 
Methylation Kit™ per the manufacturer’s instructions (Zymo Research Corp., USA). 
Quantitative, loci-specific methylation of the bisulfite modified DNA was assessed using 
the Infinium HumanMethylation27 BeadArray™ (Illumina Inc, San Diego, CA) according 
to the manufacturer’s guidelines. The array interrogates 27,578 CpG loci located in more 
than 14,000 genes. For each CpG site, two different probes are hybridized with the 
bisulfite modified DNA (one against the methylated site and one against the 
24 
 
unmethylated site). Next, a single-base extension adds one of two possible fluorescent 
probes (one for methylated (C) and one for unmethylated (T) alleles). Methylation status 
is then represented by a beta value which is calculated from the ratio of fluorescent 
signals from methylated to the sum of methylated and unmethylated probes and ranges 
from 0 (unmethylated) to 1 (methylated). Background normalization was done according 
to the guidelines recommended by Illumina using the GenomeStudio Methylation 
module. In short, this method subtracts the average signal of the negative control bead-
types from the probe signals. Normalized beta values were then output and used in 
subsequent analyses. Heat maps were generated with the MultiExperiment Viewer (113, 
114).  
A subset of samples was run in duplicate in order to assess inter-chip variability. 
In addition, CpGenome Universal Methylated DNA (Millipore, Temecula, CA) was 
bisulfite treated and run with the methylation assay as a positive control. Inter-chip 
variability was found to be highly reproducible. Pearson correlation coefficients were 
greater than 0.99 for each set of replicates (p<0.0001). In addition to running a positive 
control to ensure bisulfite conversion and accuracy of methylation, internal validity was 
assessed by examining gender specific methylation of 6 x-linked housekeeping genes 
(EFNB1, ELK1, FMR1, G6PD, GPC3, GLA) (115, 116).Overall, methylation of these 6 
genes was as expected in that females exhibited hemimethylation and males had very 
little methylation at the loci in these genes (p<0.0001 for each gene). Figure 2.1 depicts 
the gender specific methylation patterns of these 6 housekeeping genes. 
 
Cotinine assessment 
In utero exposure to tobacco smoke (through either passive or active smoking) 
was evaluated by measuring cotinine, a metabolite of nicotine, in plasma from umbilical 
cord blood. Cotinine has a long half-life and has been previously validated as a 
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biomarker of tobacco exposure; therefore, it is the gold standard measure of tobacco 
smoke exposure (117-119). A solid phase competitive ELISA was used to assess 
cotinine level (Calbiotech, California). All samples were run in duplicate with controls and 
standards per the manufacturer’s instructions. In short, 10 µl of plasma sample was 
combined with 100 µl of enzyme conjugate, mixed, and incubated for 60 minutes at room 
temperature in the dark. Samples were then washed with distilled water and residual 
moisture removed. After adding 100 µl of substrate reagent, the samples were incubated 
for 30 minutes in the dark and 100 µl of stop solution was added. Absorbance was read 
on a plate reader at 450nm. 
 
Statistical analyses 
Demographic and clinical variables were classified as follows: parity (nulliparous 
or multiparous), and race (black or non-black), prenatal care (adequate or not), labor and 
delivery complications (yes or no), and infant sex (male or female). Gestational age was 
assessed using both the clinical estimate and date of last menstrual period.  Small for 
gestational age (SGA) was used as a surrogate indicator of intrauterine growth 
restriction. The birth weight percentiles for gestational age created by Alexander et al. 
were used to classify infants as SGA (<10th percentile for a given gestational age), 
appropriate for gestational age (AGA) (10-90th percentile), or large for gestational age 
(LGA) (>90th percentile) (16). Demographic and clinical variables of were compared 
between SGA and non-SGA infants (AGA and LGA infants) using fisher’s exact test. 
Methylation level was measured at multiple CpG sites for CYP1A1 and HIF1A; 
therefore, DNA methylation level for each CpG site was averaged over the gene of 
interest. In analyses examining the risk of SGA, DNA methylation was treated as a 
continuous variable so that we could assess the impact of several methylation levels on 
SGA risk.  However, in analyses examining the impact of cigarette smoke exposure on 
26 
 
level of DNA methylation, DNA methylation was dichotomized as hypermethylated (≥75th 
percentile) or unmethylated (<75th percentile).  There is currently no consensus on what 
level of methylation is indicative of hypermethylation and the 75th percentile was chosen 
so that we could adequately differentiate infants with the highest levels of methylation 
(120, 121). Although infants are considered exposed to cigarette smoke when the 
umbilical cord cotinine level is greater than 1ng/ml, 5 ng/ml and 14 ng/ml increases in 
cotinine levels are more indicative of active cigarette smoking (119, 122, 123). 
Therefore, these cut-points were used in our analyses examining cigarette smoke 
exposure and its association with DNA methylation. 
A t-test was used to compare the mean methylation levels of each gene of 
interest between SGA and non-SGA infants as well as between infants exposed and 
unexposed to cigarette smoke. Logistic regression was used to compute adjusted odds 
ratios and 95% confidence intervals for the association between 1) SGA and the 
methylation level and 2) methylation level and cigarette smoke exposure. In logistic 
regression models, covariates and potential confounders were treated as continuous 
variables whenever possible (e.g.cotinine level, maternal age). The contribution of each 
differentially methylated gene of interest was assessed independently. Adjusted models 
controlled for covariates and potential confounders. Confounders were identified by 
comparing the crude and adjusted odds ratios. If the estimate changed by more than 
10%, the variable was adjusted for. Dose-response trends were assessed with the 
Cochran-Armitage trend test and by generating effect estimates for different levels of 
exposure.  All tests of hypothesis were two-tailed with a type 1 error rate fixed at 5 
percent. SAS version 9.1 (SAS Institute, Cary, NC) was used to perform all analyses. 
This study was approved by the University of South Florida Institutional Review Board.  
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Results 
After excluding infants with missing data (n=1) and birth defects (n=1), 90 infants 
were included in the analysis, of which 11.11% (n=10) were SGA and 88.89% (n=80) 
were non-SGA.  Table 2.1 presents maternal and infant covariates of SGA and non-SGA 
infants. Almost 30% of black infants as opposed to 5.80% of non-black infants were SGA 
(p=0.01) When compared to non-SGA infants, SGA infants were more likely to be female 
(p=0.01). The cotinine levels of the 11 exposed infants ranged from 1.00ng/ml to 
100ng/ml, with an overall mean of 36.43ng/ml. However, the mean cotinine level was 
higher among SGA infants (11.80 ng/ml) than non-SGA infants (3.53 ng/ml). 
A heat map representing the methylation level for the CpG sites used to 
determine the gene-specific methylation level for each sample is depicted in Figure 2.2. 
This figure also depicts the positive control DNA for which the sample was almost 
completely methylated as expected. Mean methylation of the 4 genes of interest 
(CYP1A1, HIF1A, GSTM1, GSTT1) ranged from 0.04 (standard deviation (SD)=0.02) for 
HIF1A to 0.10 (SD=0.10) for GSTM1. Mean methylation levels by SGA and smoking 
status are presented in Figure 2.3. Visual inspection suggested that there was little to no 
difference in methylation level by SGA or smoking status in the CYP1A1 or HIF1A 
genes. There appeared to be marginal differences by SGA status in the GSTM1 gene 
whereas GSTT1 had the greatest variation in methylation level by for both SGA and 
smoking status. Furthermore, when data were compared by methylation level few 
differences in maternal and infant characteristics were found (data not shown). However, 
of the non-black infants, 20.29% had hypermethylation of GSTT1 whereas of the black 
infants 42.86% had hypermethylation of GSTT1 (p=0.05). In addition, of the infants with 
complications, 40.74% had hypermethylation of CYP1A1 whereas only 17.46% of infants 
without complications had hypermethylation of CYP1A1 (p=0.03). 
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In both crude and adjusted logistic regression models, only 1 of the 4 genes was 
significantly associated with SGA (Table 2.2). A 0.01 unit increase in methylation of the 
GSTT1 gene was associated with an increased risk of SGA (OR=1.10, 95%CI=1.03, 
1.18) and the association appeared to be dose dependant. The risk of SGA was most 
pronounced among infants with the highest methylation levels of GSTT1 as the risk of 
SGA increased with increasing methylation (p<0.001). A 0.05 unit increase in 
methylation level was associated with a 22% increased risk of SGA (OR= 1.22, 
95%CI=1.06, 1.40), and a 0.10 unit increase in methylation increased the risk of SGA 
almost 3-fold (OR=2.69, 95%CI=1.34, 5.43). Increased methylation of the HIF1A gene 
appeared to increase the risk of SGA, but the association did not reach statistical 
significance in either crude (OR=1.23, 95%CI=0.88, 1.72) or adjusted analyses 
(OR=1.59, 95%CI=0.99, 2.56).  
Table 2.3 presents the crude and adjusted odds ratios and 95% confidence 
intervals for the association between hypermethylation (methylation level greater than or 
equal to the 75th percentile) and prenatal smoking. Prenatal smoking as measured by a 
5 ng/ml increase in cotinine level was not associated with methylation level of CYP1A1 
(OR=0.99, 95%CI=0.85, 1.16), HIF1A (OR=1.08, 95%CI=0.94, 1.24), or GSTM1 
(OR=0.94, 95%CI=0.77, 1.16). Similarly, a 14 ng/ml increase in cotinine was not 
associated with hypermethylation of the same three genes (CYP1A1, HIF1A, and 
GSTM1). However, methylation of GSTT1 was associated with smoking. A 5 ng/ml 
increase in cotinine level was associated with an 18% increased risk of hypermethylation 
(OR=1.18, 95%CI=1.02, 1.37) and a 14 ng/ml increase in cotinine level was associated 
with a 60% increased risk of hypermethylation of GSTT1 (OR=1.59, 95%CI=1.04, 2.42). 
Further, the risk of hypermethylation increased with increased cotinine level (p=0.02) 
whereby a 20 ng/ml increase in cotinine increased the risk of hypermethylation 2-fold 
(OR=1.94, 95%CI=1.06, 3.53) and a 30.0 ng/ml increase in cotinine level was 
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associated with a 2.7 fold increased risk of hypermethylation (OR=2.70, 95%CI=1.10, 
6.64).  
 
Discussion 
This study found that the risk of SGA increased with increasing methylation of the 
GSTT1 gene. GSTT1 is important in fetal response to hypoxia and metabolism of 
environmental contaminants, thus it is interesting to note that methylation of GSTT1 was 
also associated with cigarette smoke exposure. 
Few studies have examined the impact of methylation changes in DNA isolated 
from umbilical cord blood in relation to fetal outcome or fetal exposures. Two previous 
studies reported associations between prenatal tobacco smoke exposure and DNA 
methylation. Terry et al found higher levels of global methylation in exposed infants 
whereas Breton et al found lower levels of methylation in AluYb8 and higher methylation 
8 other genes, though none of the genes were the same as those examined in the 
present study (85, 108). Although the study by Terry et al examined global methylation 
changes rather than gene-specific changes as presented here, the conclusions were 
similar to ours as the authors observed that cigarette smoke exposure increases 
methylation in mononuclear cells (85). However, while promoter specific methylation is 
associated with transcriptional silencing, global methylation is more representative of 
DNA stability and cancer studies indicate that global and CpG site specific methylation 
can be quite different (i.e. global hypomethylation and CpG site specific 
hypermethylation can coexist) (124).  
Although previous studies have identified methylation changes in other genes 
associated with IUGR, to our knowledge previous studies have not examined the risk of 
SGA in relation to methylation of CYP1A1, HIF1A, GSTT1, or GSTM1 in DNA from 
umbilical cord blood-derived nucleated cells (125, 126).  Although the association 
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between HIF1A and SGA did not reach statistical significance, this study may have been 
under-powered to detect an association. Loss of expression of HIF1A may impact the 
ability of the developing fetus to respond to hypoxia, thus it is biologically plausible that 
methylation of HIF1a may contribute to IUGR risk. HIF1a expression is critical for 
downstream activation of a number of genes involved in cell growth and viability as well 
as in vascularization, factors critical for normal fetal growth (98). Abnormal methylation 
of HIF1a may suppress HIF1a and lead to fetal growth inhibition. Further, it has been 
shown that the expression of HIF1a is epigenetically regulated (84). Additional studies 
with larger samples sizes are needed to assess the association between methylation of 
HIF1A and SGA.  
Loss of GSTT1 expression could inhibit detoxification of xenobiotics, increasing 
the risk of IUGR. Hypermethylation of GSTT1 may decrease GSTT1 expression, causing 
an excess of phase 1 metabolites and increased oxidative stress (127, 128). In turn, this 
may lead to the formation of DNA adducts, cellular damage, or altered cell signaling 
(127). Although these findings have not yet been replicated, it is conceivable that SGA 
manifests in response to adverse uterine conditions via a methylation-mediated 
mechanism. The reported association between cigarette smoke exposure and 
hypermethylation of GSTT1 further supports the proposed mechanism as 
hypermethylation may alter gene expression and allow the accumulation of reactive 
oxygen species. Unfortunately, our small sample size prevented us from conducting a 
mediation analysis. In addition, our study did not examine the effects of differential 
methylation on gene expression, thus additional studies are needed to examine the 
impact of methylation changes on gene expression.  
This study has several strengths including its use of cotinine to assess cigarette 
smoke exposure. Due to societal stigmas associated with maternal smoking during 
pregnancy, many women underreport prenatal smoking. Our study overcomes this bias 
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by evaluating smoking status with a previously validated biomarker, cotinine, a 
metabolite of nicotine (119). It has been successfully measured in umbilical cord blood 
by several studies and enables investigators to quantify active and passive exposure to 
tobacco smoke (119). Cotinine in umbilical cord blood only represents exposures during 
the end of pregnancy, thus the exposure estimates may underestimate the true 
exposure level as some women may have quit smoking early in pregnancy. As a result, 
our risk estimates may be biased toward the null.  
In spite of this study’s strengths, several limitations merit mention. We used a 
state-of-the-art, high-throughput methylation array to assess over 27,000 CpG loci.  It 
has been reported that some CpG sites assessed in this array may fall within 
polymorphic sites, which may interfere with our method used to assess methylation (129, 
130). The net impact of SNPs on methylation assessments that rely on bisulfite modified 
DNA remains unclear, thus the implications of SNPs corresponding to CpG sites 
included from the four genes of interest in this study is unknown. However, SNPs are 
rare and should not significantly alter study results. We were also unable to control for 
gene polymorphisms that may impact the risk of SGA or response to cigarette smoke. 
However, several recent studies suggest that polymorphisms in CYP1A1, GSTT1, and 
the GSTM1 genes have little or no impact on the association between IUGR and 
cigarette smoke exposure, although the literature is somewhat inconsistent (79, 80, 
128).  
 This study relies on derivations from birthweight and gestational age to classify 
infants as SGA. Inaccuracies in gestational age measurement can affect how infants are 
classified. The clinical estimate can be calculated in several different ways, some of 
which are more accurate than others (131). Wingate et al. noted that clinical estimates 
and LMP differ in about 50% of the population studied and that the discordance varied 
by race and ethnicity, thus there may be some degree of non-differential 
32 
 
misclassification (131). However, the authors also noted that LMP is an imperfect 
measure as well due to recall errors and bleeding early in pregnancy (131). Although 
these indicators have faults, they are commonly employed, and in the absence of serial 
ultrasound measurements (the gold standard for IUGR classification), they are the best 
measure available (17). To ensure that factors associated with extreme prematurity did 
not influence our results, we re-ran the analyses excluding infants less than 32 weeks of 
gestation. However, the measures of association remained relatively unchanged when 
excluding them from the analysis (data not shown). However, it is important to note that 
the association between methylation of HIF1A and SGA was significant after excluding 
extremely preterm infants (OR=1.62, 95%CI=1.05, 2.60). 
Overall, this is the first study to evaluate the methylation status of 4 detoxifying 
genes in umbilical cord blood and assess the association with SGA. The associations 
between SGA and DNA methylation and smoking and DNA methylation found here 
should be investigated further using larger samples. A better understanding of the 
impact of methylation change on gene expression and risk of SGA may lead to more 
targeted intervention methods. For example, investigation and development of methods 
to prevent adverse epigenetic changes may decrease the risk of SGA among infants 
born to smokers. 
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Table 2.1 Demographic and clinical variables by SGA status 
 
 SGA1 (n=10) Non-SGA (n=80) p-value
 n % n %  
Parity      
 Nulliparous 5 17.24 24 82.76 0.28 
 Multiparous 5 8.20 56 91.80  
Race      0.01 
 Black 6 28.57 15 71.43  
 Non-black 4 5.80 65 94.20  
Pregnancy complications2     0.72 
 Yes 2 7.41 25 92.59  
 No 8 12.70 55 87.30  
Adequate prenatal care3     0.21 
 Yes 6 8.45 65 91.55  
 No 4 21.05 15 78.95  
Prenatal vitamin use     1.00 
 Yes 8 10.96 65 89.04  
 No 2 11.76 15 88.24  
Infant sex     <.01 
 Male 1 1.96 50 98.04  
 Female 9 23.08 30 76.92  
 Mean  SD4 (±) Mean  SD (±)  
Cotinine level (ng/ml) 11.80 25.24 3.53 14.57 0.33 
Maternal age 24.90 4.33 28.99 6.58 0.06 
Gestational age 38.10 1.52 38.18 2.30 0.92 
1SGA=small for gestational age 
2 This includes the presence of diabetes, gestational diabetes, preeclampsia, placental 
previa, or hypertension 
3 As reported in the medical record 
4SD=standard deviation 
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Table 2.2 Risk of SGA associated with a 0.01 unit increase in methylation level 
 
 OR1 95%CI2 OR 95%CI 
CYP1A13 0.87 0.49, 1.55 0.97 0.41, 2.29 
HIF1A3 1.23 0.88, 1.72 1.59 0.99, 2.56 
GSTM14 0.97 0.90, 1.05 1.01 0.93, 1.09 
GSTT14 1.08 1.03, 1.13 1.10 1.03, 1.18 
 
1OR=odds ratio   
2CI=confidence interval 
3 The adjusted odds ratio controls for gender, smoking, prenatal care, race, maternal 
age, and parity 
4 The adjusted odds ratio controls for smoking, prenatal care, race, maternal age, and 
parity 
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Table 2.3 Impact of a 5ng/ml and a 14ng/ml increase in cotinine level on the risk of 
hypermethylation  
Cotinine level: 5ng/ml 14 ng/ml  
 Crude Adjusted Adjusted 
 OR1 95%CI2 OR3 95%CI OR 95%CI 
CYP1A1 0.99 0.85, 1.16 0.99 0.85, 1.16 0.98 0.63, 1.53 
HIF1A 1.05 0.92, 1.20 1.08 0.94, 1.24 1.25 0.85, 1.84 
GSTM1 0.93 0.76, 1.13 0.94 0.77, 1.16 0.85 0.48, 1.50 
GSTT1 1.16 1.00, 1.35 1.18 1.02, 1.37 1.59 1.04, 2.42 
1OR=odds ratio 
2CI=confidence interval 
3 The adjusted odds ratio controls for maternal age and race 
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Figure 2.1 Methylation of selected housekeeping genes by gender   
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Figure 2.2 Heat map depicting the methylation level of all loci used to calculate the gene-specific methylation level for each sample 
and the control DNA 
 
1The smokers are represented by the darker shade of teal 
2The SGA (small for gestational age) infants are represented by the darker shade of purple 
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Figure 2.3 Mean methylation of selected genes by SGA and smoking status 
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CHAPTER THREE 
Manuscript 2: Is there an association between birthweight and DNA methylation of 
IGF1 and IGF2? 
 
Abstract 
Objective: To evaluate the association between DNA methylation of IGF1 and IGF2 and 
birthweight. 
 
Study Design: Medical record data and biological samples from 92 singletons were 
obtained from an ongoing, cross-sectional study. Methylation of DNA extracted from 
umbilical cord blood was measured with the Illumina Infinium Methylation27 assay. 
Univariate and multivariable linear regression were used to assess the impact of 
methylation on percent change in birthweight. 
 
Results: The 90 infants included in the study had a mean birthweight of 3242 grams and 
a mean gestational age of 38 weeks. After adjusting for gender, maternal age, parity, 
and pregnancy complications, a one standard deviation increase in methylation of IGF1 
decreased birthweight by 3.63% (95%CI= -6.49, -0.78). Birthweight was not associated 
with increased methylation of IGF2, even after adjusting (β= 0.07, 95%CI= -2.91, 3.05).  
 
Conclusion: Methylation of IGF1, but not IGF2 influences birthweight and may be an 
important target for interventions aimed at preventing low birthweight. 
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Introduction 
Birthweight is an important indicator of fetal growth and is associated with infant 
mortality, though the association is unlikely to be causal (22). Low birthweight infants 
(less than 2500 grams) have a higher infant mortality rate than their normal weight 
counterparts with the infant mortality rate of low birthweight infants being more than 110 
times that of infants with normal birthweights (greater than or equal to 2500 grams) 
(132). Further, low birthweight infants have a higher risk of several adult-onset diseases. 
For example, birthweight is associated with elevated blood pressure, diabetes, and heart 
disease later in life (3, 133-135). As a result, it is important to understand the factors that 
mediate fetal growth and birthweight and currently the mechanism by which poor fetal 
growth manifests in response to environmental factors is unclear, but the insulin like 
growth factor (IGF) system appears to play an important role. 
The IGF system regulates fetal and placental growth, promoting cell growth and 
differentiation and inhibiting apoptosis (8, 9). Although the IGF system includes insulin, 
several binding proteins, and multiple receptors, studies suggest that IGF1 and IGF2 are 
critical drivers of fetal growth. IGF2 is an imprinted gene that is expressed only from the 
paternal allele in most fetal tissues (88). Knockout studies of IGF1 or IGF2 suggest that 
it decreases fetal weight in mice and partial deletion of IGF1 in humans has similar 
effects (8, 11).  However, prenatal IGF2 expression is greater than IGF1 and expression 
of IGF2 changes postnatally as it becomes biallelic (8, 88). IGF1 and birthweight are 
positively associated and growth restricted infants have low umbilical cord blood levels 
of IGF1 compared to their counterparts with normal growth (11, 93, 94). Given this, it is 
conceivable that altered expression of IGF1 or IGF2 may be associated with altered fetal 
growth.  
Epigenetic modifications, namely DNA methylation, are a biologically plausible 
mechanism by which environmental and nutritional factors mediate gene expression to 
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impact phenotype, including birthweight. Findings of recent studies such as that of 
Steegers-Theunissen et al support this theory as they reported that infants exposed 
perinatally to folic acid had higher methylation of the IGF2 DMR (differentially methylated 
region) than their unexposed counterparts (10). In addition, a methylation increase of 
1.7% in the IGF2 DMR was associated with decreased birthweight (10). However, it is 
possible that the time of sampling (about 17 months after delivery) impacted methylation 
of IGF2 as IGF2 expression changes after birth (8, 10, 88). Similarly, prenatal exposure 
to famine has also been associated with decreased methylation of IGF2 (96). Although 
epigenetic control of IGF1 has received less attention, animal studies suggest that IGF1 
methylation is altered in intrauterine growth restricted (IUGR) rats and that 
hypermethylation decreases IGF1 expression (93).  
The association of birthweight with lifelong health consequences such as 
diabetes and heart disease underscores the importance of understanding the 
mechanisms that are the foundation of fetal programming (136, 137). Therefore, we 
sought to examine the relationship between birthweight and DNA methylation of IGF1 
and IGF2. 
 
Methods 
Study sample and data collection 
All study participants in this cross-sectional study were enrolled at Tampa 
General Hospital in Tampa, Florida as part of a larger ongoing study examining 
lymphocyte subpopulations and prematurity. All pregnant females delivering at Tampa 
General Hospital were eligible to participate in the Lymphocyte Study. However, infants 
born to women whose prenatal tests indicated that they were HIV positive or Hepatitis B 
positive were excluded. Maternal race and ethnicity are not factors for inclusion. For the 
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present study, infants with birth defects were excluded and only singleton infants were 
eligible for inclusion. 
De-identified demographic and clinical variables initially collected via medical 
record abstraction using standardized forms as part of the parent study were also 
obtained. The data elements collected include: gestational age, infant birthweight, infant 
sex, presence of infection, delivery complications, presence of birth defects, plurality, 
parity, gravidity, prenatal care usage, maternal age, and race. 
 
Umbilical cord blood collection 
In addition to medical record data, the Lymphocyte study also collected umbilical 
cord blood samples. After delivery of the placenta, umbilical cord blood was collected in 
tubes containing EDTA. During cord blood collection, no contact with the mother or 
infant occurred. Samples were processed at the University of South Florida within 24 
hours of collection. Plasma was removed and stored at -80°C for subsequent cotinine 
analysis. The mononuclear layer was isolated using a ficoll gradient. After separation, 
samples were suspended in fetal bovine serum and 10% DMSO and stored in liquid 
nitrogen. Long term storage of cryopreserved cells does not impact cell viability or 
recovery as previous studies have indicated that more than 80% of nucleated cells can 
be recovered (110).  
 
DNA isolation and methylation assessment 
DNA isolation and methylation assessment was performed at Wayne State 
University Applied Genomics Technology Center. Laboratory personnel were blinded to 
birth outcome and other maternal and infant health indicators. DNA was isolated from 
the mononuclear fraction of umbilical cord blood using the Qiagen EZ1 DNA tissue kit 
according to Lum et al with the exception that PBS (phosphate buffered saline) was 
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substituted for TE (tris ethylenediaminetetraacetic acid) buffer (111). The mononuclear 
fraction is largely comprised of monocytes and lymphocytes, but also contains 
hematopoietic stem cells (112).  Methylation changes in DNA from nucleated cells 
derived from umbilical cord blood should reflect changes that occurred in relation to the 
fetal environment. The Trinean Dropsense96 was used to quantify DNA after extraction. 
Bisulfite modified DNA was prepared using the EZ-96 DNA Methylation Kit™ 
according to the manufacturer’s instructions (Zymo Research Corp., USA). Quantitative, 
loci-specific methylation was assessed using the Infinium HumanMethylation27 
BeadArray™ (Illumina Inc, San Diego, CA) per the manufacturer’s instructions. The 
array interrogates 27,578 loci located in more than 14,000 genes. For each CpG site, 
two different probes (one against the methylated site and one against the unmethylated 
site) are hybridized with the bisulfite modified DNA. Next, a single-base extension adds 
one of two possible fluorescent probes (one for methylated (C) and one for unmethylated 
(T) alleles). Methylation status is then represented by a beta value which is calculated 
from the ratio of fluorescent signals from methylated to the sum of methylated and 
unmethylated probes and ranges from 0 (unmethylated) to 1 (methylated).  
Background normalization was done according to the guidelines recommended 
by Illumina using the GenomeStudio Methylation module. In short, this method subtracts 
the average signal of the negative control bead-types from the probe signals. 
Normalized beta values were then output for use in subsequent analyses. Heat maps 
were generated with the MultiExperiment Viewer (113, 114). In this study, we are 
focused on the methylation status of IGF1 and IGF2; therefore we are only analyzed 6 
CpG loci.  The nucleotide positions of 5 of the 6 the CpG sites included in this analysis 
were located in the CpG islands at chr11: 2,110,452-2,111,041 and chr11:2,115,427-
2,119,259  and the other was in chr12:101,398,416 in NCBI build 36.1. 
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A subset of samples was run in duplicate in order to assess inter-chip variability. 
In addition, CpGenome Universal Methylated DNA was used as a positive control 
(Millipore, Temecula, CA) and was bisulfite treated and run with the methylation assay. 
The positive control was used to ensure bisulfite conversion and accuracy of methylation 
measurement. The positive control DNA was almost completely methylated as expected. 
Inter-chip variability was assessed and was found to be highly reproducible. Pearson 
correlation coefficients were greater than 0.99 for each set of replicates (p<0.0001). 
Internal validity was assessed by examining gender specific methylation of 6 x-linked 
housekeeping genes (EFNB1, ELK1, FMR1, G6PD, GPC3, GLA) (115, 116). Overall, 
methylation of the 6 aforementioned housekeeping genes was as expected in that 
females exhibited hemimethylation and males had very little methylation at the loci in 
these genes (p<0.0001 for each gene).  
 
Statistical analyses 
Demographic and clinical variables were classified as follows: parity (nulliparous 
or multiparous), race (black or non-black), prenatal care (adequate or not as recorded in 
the medical record), pregnancy complications (yes or no), and infant sex (male or 
female). Prenatal vitamin use was dichotomized as yes or no as recorded in the medical 
record. Gestational age assessment was based on clinical estimate and the date of last 
menstrual period. Tobacco smoke exposure was assessed by measuring cotinine, a 
metabolite of nicotine. Gestational age, cotinine level and maternal age were kept as 
continuous variables. 
Methylation level was measured at one CpG site in the IGF1 gene and multiple 
CpG sites in the IGF2 gene. The association between methylation of each gene as well 
as each CpG site in the IGF2 gene and infant birthweight was assessed independently. 
The association between methylation of the complete IGF2 gene and birthweight was 
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assessed by averaging the methylation levels (i.e. the illumina beta values) from each 
CpG site across the gene. In order to ease interpretation, Illumina beta values were 
converted to z-scores.  
Univariate linear regression was used to assess the unadjusted association 
between birthweight and DNA methylation of the IGF1 gene, the IGF2 gene, and each 
CpG site measured in the IGF2 gene. Multivariable linear regression models were then 
constructed to control for primary predictors and potential confounders. The response 
variable, birthweight, did not initially meet all the assumptions of linear regression, 
therefore birthweight was log transformed to achieve normality. As a result, the reported 
effect estimates indicate the percent change in mean birthweight per standard deviation 
change in methylation. Confounders were identified by examining the significance of the 
covariate upon addition to the unadjusted model. If the p-value was less than 0.05, the 
variable was adjusted for. The final models were adjusted for gender, maternal age, 
parity, gestational age, and pregnancy complications. All hypothesis tests were two-
tailed with a type 1 error rate fixed at 5 percent. SAS version 9.1 (SAS Institute, Cary, 
NC) was used to perform all analyses. This study was approved by the University of 
South Florida Institutional Review Board.  
 
Results 
In total, 2 infants were excluded from the analysis because of missing data or 
presence of birth defects. The mean birthweight of 90 infants included in the analysis 
was 3242.27 grams (Standard Deviation (SD)=654.18 grams) (Table 3.1). The mean 
gestational age was 38.17 weeks (SD=2.22). A majority of the women (>80%) used 
prenatal vitamins and about 32% were nulliparous. 
Methylation was measured at 5 CpG sites in the IGF2 gene. The average 
methylation of IGF1, IGF2, and the 5 CpG sites measured in the IGF2 gene are 
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presented in Table 3.2. The methylation levels of the CpG sites range from a minimum 
of 0.02 to a maximum of 0.52. The overall methylation of the IGF2 gene was 0.24 
(SD=0.02), which was slightly lower than that of IGF1 (mean=0.26, SD=0.05). The 
methylation level was variable in the IGF2 gene, with CpG site 3 having the lowest 
methylation (mean=0.02) and CpG site 2 having the highest level of methylation 
(mean=0.52). The heat map in Figure 3.1 depicts the differential methylation of all the 
CpG sites for which methylation was measured (includes sites in both IGF1 and IGF2).  
In univariate linear regression models, all CpG sites except CpG site 5 suggested 
that birthweight decreased with increasing methylation (Table 3.3). Methylation of the 
entire IGF2 gene reflected this trend, but the association was not significant (β= -0.62, 
95%CI= -5.75, 4.51). Similar results were found for IGF1 (β= -4.05, 95%CI=-9.11, 1.01). 
CpG site 3, the site with the lowest mean methylation, was the only site that was 
significantly associated with birthweight. Every one standard deviation increase in 
methylation was associated with a 5.10% decrease in birthweight. However, after 
adjusting for gender, maternal age, parity, gestational age, and pregnancy 
complications, the association between birthweight and methylation of CpG site 3 was 
no longer significant (β=-1.82, 95%CI= -4.81, 1.16). The association between percent 
change in birthweight and one standard deviation increase in methylation of the IGF2 
gene remained non-significant (β= 0.07, 95%CI= -2.91, 3.05) as did the associations 
between methylation of each of the other CpG sites in the IGF2 gene and birthweight. 
After adjusting for confounders, methylation of IGF1 was significantly associated with 
birthweight and one standard deviation increase in methylation of IGF1 decreased 
birthweight by 3.63% (95%CI= -6.49, -0.78).  
Initial assessments indicated that race was not a confounder and therefore it was 
not included in the multivariable models. However, we sought to explore this further and 
re-ran the analysis including race as well as the other confounders (gender, maternal 
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age, parity, gestational age, and pregnancy complications). This did not appreciably alter 
the results or the conclusions; therefore race was not included in the final multivariable 
model (data not shown). 
 
Discussion 
 We found that birthweight is associated with methylation of the IGF1 gene, but 
not the IGF2 gene. A one standard deviation increase (SD=0.05) in methylation of the 
IGF1 gene decreased birthweight by 3.63%. Partial deletion or knockout of IGF1 has 
been shown to decrease birthweight in animal models, thus if IGF1 was epigenetically 
silenced, similar findings would be expected (8, 11). Although we did not measure IGF1 
expression, the methylation site that was assessed was near the transcription start site, 
so it is likely that methylation would impact expression, but additional studies are needed 
to confirm this.  
Previous studies have reported an association between birthweight and folic acid 
use and folic acid has been shown to increase gene-specific methylation, thus it is 
plausible that a methylation mediated mechanism controls fetal growth (10, 15, 61, 62, 
138). Interestingly, prenatal vitamin use, a surrogate indicator of folic acid intake, did not 
significantly impact the association between birthweight and methylation of the IGF1 or 
IGF2 gene in our regression models. Our small sample size precluded a detailed 
investigation of this, but results from analyses examining methylation of IGF1 and IGF2 
stratified by prenatal vitamin use were similar to that of the unstratified analysis, but in 
most cases did not reach statistical significance (data not shown). Further, 3 women in 
this study used high dose folic acid supplements during pregnancy and the mean 
methylation levels of these infants did not differ from those of regular prenatal vitamin 
users or non-users (data not shown). Nonetheless, our assessment of folic acid intake 
was limited to information abstracted from the medical record. We did not have any 
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information regarding the trimester that prenatal vitamin use began, the actual dose 
received, or dietary folic acid intake, thus these results must be interpreted with caution.  
  Few previous studies have examined methylation of IGF2 and birthweight. Our 
results conflict with those of Steegers-Theunissen et al as they found that increased 
methylation of IGF2 decreased birthweight after controlling for periconceptional folic acid 
use and gestational age whereas we did not find an association (10). In contrast, a study 
by Tabano et al examined methylation in DNA from umbilical cord blood of 60 normal 
and 66 IUGR infants (139). Although the study examined a different indicator of fetal 
growth (IUGR as opposed to birthweight) the results were similar to those found here in 
that infants had similar methylation levels in the IGF2/H19 imprinted region regardless of 
whether the infant was growth restricted (139). Other factors may interact with IGF2 to 
modulate fetal growth. A study by Ong et al reported a relationship between umbilical 
cord blood levels of IGF2 and the IGF2 receptor and that when considered together, 
these factors were significantly associated with birthweight (140). Alternatively, one 
previous study suggested that methylation of the IGF2 gene is highly conserved, thus it 
is possible that more extreme changes in methylation of IGF2 may only be associated 
with other outcomes not captured in this study such as Beckwith-Wiedermann syndrome 
or miscarriage (139). 
Although this unique study provides much needed information on how 
methylation of two important genes in the IGF system influence birthweight, several 
limitations merit mention. We used a state-of-the-art, high-throughput methylation array 
to assess over 27,000 CpG loci. It has been reported that some CpG sites fall within 
polymorphic sites and may interfere with our method used to assess methylation (129, 
130). The net impact of SNPs on methylation assessments that rely on bisulfite modified 
DNA remains unclear, but in this study, there were no known SNPs in 4 of the 6 CpG 
sites assessed. The implications of SNPs corresponding to the remaining 2 CpG sites 
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included from the two genes of interest in this study is unknown. However, SNPs are 
rare and should not significantly alter study results. The small sample size may have 
affected study results and prevented some associations from reaching statistical 
significance, thus additional studies are needed to examine the role of epigenetics in 
fetal growth.  
An increasing number of studies are reporting an association between 
birthweight and a number of adverse health outcomes such as diabetes and heart 
disease (136, 137).  A better understanding of the mechanisms that curtail normal fetal 
growth, may lead to enhanced strategies that are able to prevent suboptimal fetal growth 
and low birthweight. The findings of the current study highlight the need for additional 
investigations into the role of epigenetic modifications in the IGF system and their 
interactions with folic acid and other methyl donors.  
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Table 3.1 Summary of maternal and infant covariates  
 
 n % 
Race   
 Black 69 76.67 
 Non-black 21 23.33 
Adequate prenatal care1   
 Yes 71 78.89 
 No 19 21.11 
Pregnancy Complications2   
 Yes 27 30.00 
 No 63 70.00 
Nulliparous   
 Yes 29 32.22 
 No 61 67.78 
Prenatal vitamin use1   
 Yes 73 81.11 
 No 17 18.89 
Gender   
 Female 39 43.33 
 Male 51 56.67 
 Mean SD (±)3 
Cotinine level (ng/ml) 4.45 16.12 
Maternal age 28.53 6.48 
Gestational age 38.17 2.22 
1 As reported in the medical record 
2 This includes the presence of diabetes, gestational diabetes, preeclampsia, placental 
previa, or hypertension 
3 SD=standard deviation 
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Table 3.2 Mean methylation level of the IGF1 gene, the IGF2 gene, and the 5 CpG sites 
in the IGF2 gene used to assess the overall methylation level 
 Mean methylation Standard Deviation 
(+/-) 
IGF1 0.26 0.05 
IGF2 0.24 0.02 
 CpG site 1 0.23 0.03 
 CpG site 2 0.52 0.04 
 CpG site 3 0.02 0.01 
 CpG site 4 0.11 0.02 
 CpG site 5 0.33 0.04 
  
52 
 
Table 3.3 Association between birthweight and DNA methylation in the IGF1 and IGF2 
genes  
 Crude Adjusted 
 Β1 95%CI3 Β1,2 95%CI 
IGF1 -4.05 -9.11, 1.01 -3.63 -6.49, -0.78 
IGF2 -0.62 -5.75, 4.51 0.07 -2.91, 3.05 
 CpG site 1 -0.31 -5.44, 4.83 -0.11 -3.09, 2.86 
 CpG site 2 -0.24 -5.37, 4.90 0.15 -2.84, 3.14 
 CpG site 3 -5.10 -10.11, -0.08 -1.82 -4.81, 1.16 
 CpG site 4 -0.54 -5.67, 4.59 -1.72 -4.67, 1.24 
  CpG site 5 0.39 -4.74, 5.53 1.25 -1.72, 4.22 
1Percent change in birthweight per standard deviation change in methylation level 
2Adjusted for gender, maternal age, parity, gestational age, and pregnancy 
complications 
3 CI=confidence interval 
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Figure 3.1 Heat map of methylated CpG sites in the IGF1 and IGF2 genes   
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CHAPTER FOUR 
Conclusions and Recommendations 
Although previous studies have found that prenatal exposures such as cigarette 
smoke and folic acid influence birthweight and SGA risk, the mechanism underlying 
these associations remains unclear (41, 61, 62, 102). One possible mechanism, DNA 
methylation, has not yet been fully explored and there is a lack of information about the 
influence of prenatal exposures on methylation patterns in DNA isolated from umbilical 
cord blood and subsequent pregnancy outcomes. This study used a candiate gene 
approach to address this gap by first examining whether methylation of CYP1A1, HIF1A, 
GSTM1, or GSTT1 modulates SGA risk and then examining the relationship between 
birthweight and methylation of IGF1 and IGF2. The study findings suggest that 
methylation may control some of the genes critical for normal fetal growth. Moreover, we 
found the risk of SGA increased with increasing methylation of GSTT1, a gene important 
for metabolism of cigarette smoke and other xenobiotics (77). Similarly, 
hypermethylation of a critical fetal growth gene, IGF1, was associated with birthweight 
decrements (8, 11).  
We also examined whether abnormal methylation could be the mechanism 
underlying previously described associations between prenatal smoking and suboptimal 
fetal growth (41, 102). Additional analyses demonstrated that smoking impacts 
methylation of GSTT1, but not CYP1A1, GSTM1, or HIF1A. This finding suggests that 
abnormal methylation may be caused by in utero exposures and supports our 
hypothesis that methylation is the mechanism underlying the association between 
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prenatal smoking and SGA. Additional studies are needed to determine if 
hypermethylation alters the expression of the GSTT gene.  
Although this unique study provides valuable information that helps fill a critical 
gap in our knowledge of the mechanisms that influences birthweight and SGA risk, it 
seemingly raises more questions than it answers. First, there is a need to further 
examine the role of folate in preventing abnormal methylation. Folate appears to have a 
beneficial role in pregnancy, decreasing the risk of neural tube defects and preventing 
low birthweight, and its role in one carbon metabolism, methylation reactions, and amino 
acid synthesis suggests that the mechanism underlying these outcomes may be tied to 
abnormal methylation (50, 52, 53). This study found that hypermethylation of IGF1 
decreases birthweight, but prenatal vitamin use did not appear to be important in the 
association. However, this study used prenatal vitamin use as a surrogate indicator of 
folic acid intake and did not consider the duration, dosage, or additional dietary sources 
of folic acid which may have masked the true association. Additional studies with more 
accurate measures of folic acid intake are needed to determine whether folic acid can 
prevent abnormal methylation and associated adverse pregnancy outcomes. 
It is also important to acknowledge the possibility that our study results may not 
translate to other populations. This study may over-represent high risk pregnancies 
since the biological and clinical data was initially collected for a different study. Some of 
the discrepancies may be attributed to the design of the parent study as the principle 
investigator of that study was based in the neonatal intensive care unit and had greater 
access to high risk pregnancies. When several key indicators for our study were 
compared to that of the county in which the hospital is located (Hillsborough) and that of 
the state, some differences were noted. Our sample had a higher proportion of low 
birthweight infants (10.00%) than that of the Hillsborough County (7.61%) or the state 
(7.04%) (141). In addition, when compared to the county, the present study had a higher 
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proportion of black infants (24.14% versus 21.00%) and a lower proportion of births to 
women under 35 years of age (80.00% versus 86.08%) (141).  
 Perhaps some of the main shortcomings of this study are its sample size and 
exploratory design. We were unable to examine how genes in the same system interact 
together to produce an adverse outcome. We hope to expand the sample size and 
obtain better indicators of folate intake. Although this study used a targeted gene 
approach to examine methylation and fetal growth indicators, we also plan to do a more 
epigenome wide approach and identify all CpG sites with a high degree of variation in 
methylation level. Although this complex, the data gathered for this study are conducive 
to such a design as this study obtained data on methylation of more than 27,000 CpG 
sites in about 14,000 different genes. 
Nonetheless, the mechanisms underlying SGA and low birthweight remain 
unclear and additional efforts are needed to increase our knowledge of the role of DNA 
methylation in mediating fetal growth as it may lead to the development of methods to 
circumvent adverse pregnancy outcomes.  
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Participant recruitment and data collection 
The Lymphocyte Study 
All participants were recruited from a larger, on-going study at Tampa General 
Hospital (TGH) which seeks to examine prematurity in relation to lymphocyte 
subpopulations in umbilical cord blood samples from infants born at TGH. Participants in 
the lymphocyte project are identified at admission to TGH for delivery. The principal 
investigator of this study, a neonatology fellow, was based in the neonatal intensive care 
unit, thus it is possible that the infants included in this study disproportionately reflect 
high risk pregnancies and deliveries. Maternal age, race, and ethnicity are not factors for 
inclusion. So as to prevent unnecessary risk, women whose prenatal tests indicated that 
they were HIV or hepatitis B positive were not eligible for this study.  
Umbilical cord blood collection occurs after delivery of the infant and afterbirth 
and involves no direct contact with the mother or infant. After delivery of the placenta, a 
transport nurse or physician wiped the umbilical cord with 70% alcohol and betadine as 
this is the needle insertion (collection) site. The needle is inserted into the umbilical cord 
and held in place while the blood from the cord flows into the attached collection tube 
containing EDTA. Approximately 3-5 mL of blood is collected, but the amount collected 
depended on the amount available. After collection, the tube was gently inverted to mix 
the cord blood with the anticoagulant. The collection tube was then labeled with the date 
of collection and the medical record number and placed into a plastic bag. This was then 
sealed and sent to the USF lab for storage and preliminary processing.  Samples were 
processed within 24 hours of collection. At the time of processing, the sample was 
assigned a study ID number and the medical record number was transcribed into the 
study log so that the medical record information could be abstracted by the principal 
investigator at a later date.  Thereafter, the samples were labeled only with the study ID 
and no personal identifiers. 
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Samples were transferred to conical tubes and spun. Then plasma was removed 
and stored in 1mL tubes at -80°C for subsequent cotinine analysis. A ficoll gradient 
separation was then used to isolate the mononuclear layer. After separation, samples 
were suspended in freeze media (fetal bovine serum and 10% DMSO) and stored in 
liquid nitrogen.  
The principal investigator of the Lymphocyte study abstracted maternal and 
infant covariates from electronic medical records (birth record) onto a standardized form 
(see Appendix B). This form includes maternal age, the infant’s gestational age, birth 
weight, presence of congenital anomalies, type of delivery, placental infection, and 
plurality (singleton vs. multiple). The form also collected information on prenatal care. 
Although this was initially planned to collected as a yes/no response, the medical record 
listed prenatal care as adequate or inadequate if there was prenatal care provided; 
therefore this information was also collected on the form.  Blood samples are linked to 
the mother-infant dyad information with a unique ID. 
 
The current project 
In this study, no contact or participation of the mother/infant dyad occurred as all 
covariates and blood samples are collected by the Lymphocyte Study. The Lymphocyte 
Study provided paper copies of the forms used to abstract medical records as well as 
frozen plasma and nucleated cell samples. The paper forms were then entered into an 
Access database. After the data was entered into the database, paper forms were 
randomly selected compared to the electronic database in order to verify that there were 
no transcription errors. The data were also inspected for out of range values. None were 
detected. In total, 92 records were entered. One infant’s medical record could not be 
located (per the principal investigator’s note) and one infant had a birth defect, thus  
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these 2 infants were excluded from the analysis as they did not meet the study criteria. 
Although the Lymphocyte Study included some multiple births, the medical record 
information for these infants was not provided. Therefore, the total number of infants in 
the present study is less than that of the parent study. 
Cotinine assays were done at the University of South Florida using a solid phase 
competitive ELISA (Calbiotech, California). All cotinine assays were performed by the 
principal investigator in duplicate per the manufacturer’s instructions. Absorbance was 
read on a Biotek Synergy 2 plate reader using Gen5 software. 
DNA isolation and methylation assessment was done at Wayne State University 
Applied Genomics Technology Center using 300ul to 500ul of cell suspension. The 
amount of DNA obtained from the cells varied greatly as the number of nucleated cells 
per microliter of freeze media varied. The variation in the number of cells in the freeze 
media is attributed to the fact that the number of cells collected was not quantified for a 
majority of the samples prior to aliquoting and freezing. The concentration of DNA 
extracted from each sample is presented in Table A.1. 
The Infinium HumanMethylation27 BeadArray™ (Illumina Inc, San Diego, CA) is 
designed so that 24 samples can be run per chip, therefore, 4 chips were required to run 
the 92 samples. Samples were run in duplicate to assess inter-chip variability, so 1 set of 
duplicates was run on chips 1 and 2, another on chips 2 and 3, and the last one on chips 
3 and 4. The 3 samples run in duplicate were: JS020, JS052, and JS079.  The samples 
were randomly selected from those samples with enough DNA for more than one 
methylation assay.  
The methylation assay requires bisulfite modified DNA which was prepared using 
the EZ-96 DNA Methylation Kit™ according to the manufacturer’s instructions (Zymo 
Research Corp., USA). The bisulfite modification step converts unmethylated cytosines  
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to uracil whereas methylated cytosines are protected by the covalently bound methyl 
group. The DNA is then amplified and applied to a chip. Quantitative, loci-specific 
methylation is assessed using the Infinium HumanMethylation27 BeadArray™ (Illumina 
Inc, San Diego, CA). The array interrogates 27,578 loci located in more than 14,000 
genes. Two different probes (one against the methylated site and one against the 
unmethylated site) are hybridized with the bisulfite modified DNA. Next, a single-base 
extension adds one of two possible fluorescent probes (one for methylated (C) and one 
for unmethylated (T) alleles). The samples are stained and scanned. Methylation status 
is then represented by a beta value which is calculated from the ratio of fluorescent 
signals from methylated to the sum of methylated and unmethylated probes and ranges 
from 0 (unmethylated) to 1 (methylated). 
Background normalization was done according to the guidelines recommended 
by Illumina using the GenomeStudio Methylation module. This method subtracts the 
average signal of the negative control bead-types from the probe signals. The median 
absolute deviation method is used to remove outliers. Step by step instructions for 
normalizing the data are detailed in the Illumina user manual. Normalized beta values 
were then output into text files and used in subsequent analyses. Heat maps were 
generated with the MultiExperiment Viewer (113, 114).  
 
Assessment of methylation analysis success 
First the methylation level of the control DNA was examined in order to ensure bisulfite 
conversion. Since this DNA was almost completely methylated as expected, I then 
assessed internal validity by examining gender specific methylation of 6 x-linked 
housekeeping genes (EFNB1, ELK1, FMR1, G6PD, GPC3, GLA) (115, 116). Overall,  
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methylation of these 6 genes was as expected in that females exhibited hemimethylation  
and males had very little methylation at the loci in these genes (p<0.0001 for each 
gene). The mean methylation level of each of the housekeeping genes by gender is 
presented in Table A.2. The Illumina Infinium assay required 4 chips, thus a subset of 
samples were run in duplicate to assess inter-chip variability. Pearson correlation 
coefficients were greater than 0.99 for each set of replicates (p<0.0001). Table A.3 
presents the correlation coefficients and p-values for each set of duplicates. 
 
Analysis of manuscript 1 
SGA and methylation level  
 A total of 90 infants were included in this analysis. Maternal and infant 
characteristics of SGA and non-SGA infants were compared using fisher’s exact test and 
t-tests as appropriate. SGA was defined as having a birthweight that is less than the 
10th percentile for a given gestational age based on the birthweight percentiles for 
gestational age created by Alexander et al. A t-test was used to compare the mean 
methylation levels of each gene of interest between SGA and non-SGA infants. Logistic 
regression was used to compute adjusted odds ratios and 95% confidence intervals for 
the association between SGA and the methylation level of each gene. The beta values 
obtained from the methylation assay were treated as continuous variables. The 
methylation of the CYP1A1 gene was determined by averaging the beta-values of 4 CpG 
sites whereas the methylation level of the HIF1A gene was determined by averaging the 
beta values of 2 CpG sites. The methylation of GSTM1 and the GSTT1 genes were each 
based on the methylation level of one CpG site. Table A.4 presents the mean, standard 
deviation, and the minimum and maximum beta values of each CpG site assessed.  
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Adjusted models controlled for covariates and potential confounders. Variables used in 
this analysis were classified as follows: 
 
1. Gender: Male or female 
2. Parity: nulliparous or multiparous 
3. Cigarette smoke exposure: Two indicators of cigarette smoke exposure were 
considered. The first (smoker) was a dichotomous variable (yes or no). Smokers 
included everyone with a cotinine level ≥1.0. Cigarette smoke exposure was also 
evaluated as a continuous variable (cotinine) by including the cotinine 
measurement in the model. 
4. Prenatal vitamin use: Yes or no as indicated in the medical record. 
5. Pregnancy complications: yes or no. Pregnancy complications included the 
presence of diabetes, gestational diabetes, preeclampsia, placental previa, or 
hypertension. 
6. Maternal age: This was left as a continuous variable. 
7. Prenatal care: This was originally classified as adequate, inadequate, or none. 
However, due to the small sample size, this was reclassified as adequate or not. 
8. Race: Race was originally classified as black, white, Hispanic, or other. However, 
the small sample size required that some of these categories be combined. 
Therefore it was reclassified as black or non-black. In addition, we examined 
race classified as black, white, or other. 
 
In this analysis, SGA was the main outcome of interest and DNA methylation of each 
gene was the primary predictor. Although DNA methylation is a possible mediator in the 
SGA-smoking relationship, we were unable to assess this because the study sample  
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had few smoke exposed SGA infants. Gender, parity, race, prenatal vitamin use, 
pregnancy complications, prenatal care, maternal age, and smoking were examined as 
potential confounders. Confounders were identified by comparing the crude and 
adjusted odds ratios. The models for the crude analysis are:  
 
logit {Pr(SGA=1|X)}=β0+β1(CYP1A1) 
 
logit {Pr(SGA=1|X)}=β0+β1(HIF1A) 
 
logit {Pr(SGA=1|X)}=β0+β1(GSTM1) 
 
logit {Pr(SGA=1|X)}=β0+β1(GSTT1) 
 
Potential confounders were added to the models one at a time and if the estimate 
changed by more than 10%, the variable was adjusted for. Table A.5 below summarizes 
the models and confounders assessed as well as the different classifications that were 
considered.  
The final models used race as a dichotomous variable (black or non-black) and 
kept variables continuous whenever possible (maternal age and cotinine level as the 
indicator of cigarette smoke exposure). The final models are: 
 
logit {Pr(SGA=1|X)}=β0+β1(CYP1A1)+β2(gender)+β3(cotinine)+β4(prenatal 
care)+β5(race)+ β6(maternal age)+β7(parity) 
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logit {Pr(SGA=1|X)}=β0+β1(HIF1A)+β2(gender)+β3(cotinine)+β4(prenatal care)+β5(race)+     
β6(maternal age)+β7(parity) 
 
logit {Pr(SGA=1|X)}=β0+β1(GSTM1)+β2(cotinine)+β3(prenatal care)+β4(race)+ 
β5(maternal age)+β6(parity) 
 
logit {Pr(SGA=1|X)}=β0+β1(GSTT1)+β2(cotinine)+β3(prenatal care)+β4(race)+ 
β5(maternal age)+β6(parity) 
 
The small sample size precluded the use of additional variable classifications. 
Both crude and adjusted estimates are reported in the final manuscript and the adjusted 
estimates controlled for confounders and covariates that previous authors found to be 
strongly associated with DNA methylation or SGA risk. Gender was the only confounder 
identified and it was included in models examining methylation of CYP1A1 and HIF1A. In 
addition, models were adjusted for smoking, prenatal care, race, maternal age, and 
parity. These variables were selected because smoking, race, and age have all be found 
to be associated with DNA methylation. Parity is frequently tied to maternal age and it as 
well as each of the other covariates has been reported to be associated with SGA risk. A 
summary of the parameter estimates and model fit statistics are presented in Table A.6. 
Dose-response trends were assessed with the Cochran-Armitage trend test and by 
generating effect estimates for different levels of exposure. This statistic is the same as 
the score test statistics in the testing global null hypothesis section of the proc logistic 
output. 
In sub-analyses related to the discussion portion of the manuscript, the impact of 
gender on the results was assessed by excluding male infants. This exclusion was done  
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because there was only 1 SGA male and gender was identified as a confounder in some 
of the analyses. The results were very similar. As in our original analysis, only 
methylation of GSTT1 was associated with SGA risk in both crude (OR=1.11, 
95%CI=1.04, 1.20) and adjusted analyses (OR=1.13, 95%CI=1.01, 1.26). Similarly, 
excluding extremely preterm infants (<32 weeks of gestation) did not markedly alter the 
interpretation of the results. The adjusted odds ratios for a 0.01 increase in methylation 
were similar for CYP1A1 (OR=1.20, 95%CI=0.48, 3.03), HIF1A (OR=1.62, 95%CI=1.05, 
2.60), GSTM1 (OR=1.00, 95%CI=0.92, 1.09), or GSTT1 (OR=1.10, 95%CI=1.03, 1.18). 
However, it is important to note that the association between methylation of HIF1A and 
SGA was significant after excluding extremely preterm infants. 
 
Hypermethylation and cotinine level 
 For this analysis, the impact of cigarette smoke exposure on DNA methylation 
was assessed using the same 90 infants in the previous analysis. In order to assess this, 
the outcome, DNA methylation, was dichotomized. The current literature on DNA 
methylation classified hypermethylation in different ways and there does not appear to 
be a consensus on what level of methylation is indicative of hypermethylation. For 
example, Dietrich et al used the median and Zhu et al used greater than the 90th 
percentile (120, 121). Although I considered using a cut-point at the mean, it was 
thought that this may not adequately differentiate infants with much higher levels of 
methylation. Therefore, infants with methylation level at or above the 75th percentile were 
compared to those with a methylation level falling below the 75th percentile. The cut 
points (based on Illumina beta values) used to differentiate between hypermethylation 
and normal methylation are: 0.0823591 (CYP1A1), 0.0409117 (HIF1A), 0.0569107 
(GSTT1), and 0.1739638 (GSTM1). 
78 
 
APPENDIX A (CONTINUED) 
Although a cotinine level greater than 1ng/ml is indicative of cigarette smoke 
exposure, we left cotinine as a continuous variable so that we could look at the impact of 
several different levels of exposure in relation to methylation.  Maternal and infant 
characteristics of infants with hypermethylation were compared to those with normal 
methylation using fisher’s exact test and t-tests as appropriate. Each gene was 
considered separately. Confounders and covariates considered for inclusion in the 
adjusted models were classified as follows: 
 
1. Gender: Male or female 
2. Parity: nulliparous or multiparous 
3. Prenatal vitamin use: Yes or no as indicated in the medical record. 
4. Pregnancy complications: yes or no. Pregnancy complications included the 
presence of diabetes, gestational diabetes, preeclampsia, placental previa, or 
hypertension. 
5. Maternal age: This was left as a continuous variable. 
6. Prenatal care: This was originally classified as adequate, inadequate, or none. 
However, due to the small sample size, this was reclassified as adequate or not. 
7. Race: Race was originally classified as black, white, Hispanic, or other. However, 
the small sample size required that some of these categories be combined; 
therefore it was reclassified as black or non-black. In addition, we examined race 
classified as black, white, or other. 
8. Gestational age: This was left as a continuous variable. 
 
Logistic regression was used to compute crude and adjusted odds ratios and 95% 
confidence intervals for the risk of hypermethylation of each gene for a given cotinine  
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level. The main outcome of interest was hypermethylation of each gene and cigarette 
smoke exposure acted as the primary predictor in this analysis. The crude models that 
were examined in this analysis are: 
 
logit{Pr(Hypermethylation of CYP1A1 =1|X)}=β0+β1(cotinine) 
 
logit{Pr(Hypermethylation of HIF1A =1|X)}=β0+β1(cotinine) 
 
logit{Pr(Hypermethylation of GSTM1 =1|X)}=β0+β1(cotinine) 
 
logit{Pr(Hypermethylation of GSTT1 =1|X)}=β0+β1(cotinine) 
 
Gender, parity, prenatal vitamin use, pregnancy complications, maternal age, prenatal 
care, race, and gestational age were examined as potential confounders. Adjusted 
models controlled for covariates and potential confounders. Confounders were identified 
by comparing the crude and adjusted odds ratios. If the estimate changed by more than 
10%, the variable was adjusted for. Table A.7 below summarizes the models and 
confounders assessed as well as the different variable classifications that were 
considered. None of the variables that we assessed were considered confounders under 
the definition described above. However, the adjusted odds ratios control for maternal 
age and race because these are important variables in continued smoking during 
pregnancy and have been associated with DNA methylation. In the final model cotinine 
was kept as a continuous variable, race was dichotomized (black or non-black) and 
maternal age was kept as a continuous variable. Crude and adjusted odds ratios are 
reported in the final manuscript. 
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The final adjusted models are: 
 
logit{Pr(Hypermethylation of CYP1A1 =1|X)}=β0+β1(cotinine)+β2(race)+β3(maternal age) 
 
logit{Pr(Hypermethylation of HIF1A =1|X)}=β0+β1(cotinine)+β2(race)+β3(maternal age) 
 
logit{Pr(Hypermethylation of GSTM1 =1|X)}=β0+β1(cotinine)+β2(race)+β3(maternal age) 
 
logit{Pr(Hypermethylation of GSTT1 =1|X)}=β0+β1(cotinine)+β2(race)+β3(maternal age) 
 
A summary of the parameter estimates and fit statistics for the crude and adjusted 
models are presented in Table A.8. The risk of hypermethylation was examined for a 
5ng/ml increase in cotinine level and a 14ng/ml increase, levels which were selected 
based on previous research. Infants are generally considered to be exposed to cotinine 
if the cord blood cotinine level is greater than 1 ng/ml (119, 122, 123). Nafstad et al 
found that 14ng/ml differentiates active and passive smokers well, but it does not 
capture occasional smokers (123). Further, the study found that an increase in one 
cigarette per day increased cotinine levels by almost 5ng/ml (4.4 ng/ml; 95% CI: 1.1-7.6) 
(123). Dose-response trends were assessed with the Cochran-Armitage trend test and 
by generating effect estimates for different levels of exposure. This statistic is the same 
as the score test statistics in the testing global null hypothesis section of the proc logistic 
output.  
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Analysis of manuscript 2 
For this manuscript we sought to examine the association between birthweight 
and methylation of the IGF2 gene, each CpG site assessed in the IGF2 gene, and the 
IGF1 gene. Birthweight, the dependant variable, was treated as continuous. Methylation 
of the IGF1 gene was based on the methylation level of one CpG site in that gene 
whereas the methylation level of the IGF2 gene was determined by averaging the 
methylation of 5 CpG sites in the IGF2 gene. Covariates were kept as continuous 
variables whenever possible. Variables considered for inclusion in the adjusted models 
were classified as follows: 
 
1. Gender: Male or female 
2. Parity: nulliparous or multiparous 
3. Prenatal vitamin use: Yes or no as indicated in the medical record. 
4. Pregnancy complications: yes or no. Pregnancy complications included the 
presence of diabetes, gestational diabetes, preeclampsia, placental previa, or 
hypertension. 
5. Maternal age: This was kept as a continuous variable. 
6. Prenatal care: This was originally classified as adequate, inadequate, or none. 
However, due to the small sample size, this was reclassified as adequate or not. 
7. Race: Race was originally classified as black, white, Hispanic, or other. However, 
the small sample size required that some of these categories be combined; 
therefore it was reclassified as black or non-black. In addition, we examined race 
classified as black, white, or other. 
8. Gestational age: This was kept as a continuous variable. 
 
82 
 
APPENDIX A (CONTINUED) 
9. Preterm birth: yes or no. Infants were considered preterm if they were less than 
37 weeks of gestation. 
10. Cigarette smoke exposure: Two indicators of cigarette smoke exposure were 
considered. The first (smoker) was a dichotomous variable (yes or no). Smokers 
included everyone with a cotinine level ≥1.0. Cigarette smoke exposure was also 
evaluated as a continuous variable (cotinine) by including the cotinine 
measurement in the model. 
 
In order to ease interpretation and ensure linearity between the outcome and 
methylation level, Illumina beta values were converted to z-scores. The z-scores were 
then used in the regression models. The validity of this transformation was assessed by 
plotting birthweight verses the transformed methylation values. The plots for IGF1 and 
IGF2 are depicted in Figures A.1 and A.2.  
First, univariate linear regression was used to assess the crude association 
between birthweight (outcome) and DNA methylation of the IGF1 and IGF2 genes 
(primary predictors). The crude models assessed were: 
 
E (Birthweight|X) = β0+β1(IGF1) 
 
E (Birthweight|X) = β0+β1(IGF2) 
 
I then checked to ensure that the normality assumption was not violated. Residuals were 
generated for the models and then plotted verses the predicted values. According to the 
Shapiro-Wilk statistic, the data were not normal for IGF2 (p= 0.0306), but IGF1 appeared 
to be normal (p= 0.0742). As a result, the outcome, birthweight, was log transformed.  
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This resulted in normally distributed data for IGF1 (p= 0.6260) and IGF2 (p=0.5548) 
based on the Shapiro-Wilk statistic. As a result of these transformations, the reported 
effect estimates indicate the percent change in the average birthweight (100*parameter 
estimate) per one standard deviation change in methylation. Crude models were then re-
run using the transformed variable. 
 
Gender, parity, prenatal vitamin use, cigarette smoke exposure, pregnancy 
complications, maternal age, prenatal care, race, and gestational age were examined as 
potential confounders. In addition, prenatal vitamin use was assessed as a possible 
moderator. I then identified potential confounders by adding each covariate to the 
unadjusted model. Each covariate was assessed independently and if the p-value 
associated with that variable was less than 0.05, the variable was adjusted for. A 
summary of the confounders assessed and their associated p-values are presented in 
Table A.9. Multivariable linear regression models were then constructed to control for 
potential confounders. The final models were adjusted for gender, maternal age, parity, 
gestational age, and pregnancy complications. 
 
E {(log(Birthweight))|X} = β0+β1(IGF1)+β2(gender)+β3(parity)+β4(gestational 
age)+β5(complication) 
 
E {(log(Birthweight))|X} =  β0+β1(IGF2)+β2(gender)+β3(parity)+β4(gestational age) 
+β5(complication) 
 
E {(log(Birthweight))|X} =  β0+β1(IGF2, CPG site1)+β2(gender)+β3(parity)+β4(gestational 
age) +β5(complication) 
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E {(log(Birthweight))|X} =  β0+β1(IGF2, CPG site 2)+β2(gender)+β3(parity)+β4(gestational 
age) +β5(complication) 
 
E {(log(Birthweight))|X} = β0+β1(IGF2, CPG site 3)+β2(gender)+β3(parity)+β4(gestational 
age) +β5(complication) 
 
E {(log(Birthweight))|X} =  β0+β1(IGF2, CPG site 4)+β2(gender)+β3(parity)+β4(gestational 
age) +β5(complication) 
 
E {(log(Birthweight))|X} =  β0+β1(IGF2, CPG site 5)+β2(gender)+β3(parity)+β4(gestational 
age) +β5(complication) 
 
A summary of the parameter estimates and fit statistics for the crude and final models 
are presented in Table A.10. Initial assessments indicated that race was not a 
confounder and therefore it was not included in the multivariable models. However, I 
sought to explore this further and re-ran the analysis including race as well as the other 
confounders (gender, maternal age, parity, gestational age, and pregnancy 
complications) in the model. This did not appreciably alter the results or the conclusions; 
therefore race was not included in the final multivariable model (Table A.11). 
 Interestingly, prenatal vitamin use, a surrogate indicator of folic acid intake, did 
not significantly impact the association between birthweight and methylation of the IGF1 
or IGF2 gene in our regression models. Our small sample size precluded a detailed 
investigation of this, but we did stratify the data by prenatal vitamin use to do an 
exploratory examination of the data. Stratified analysis suggested that the associations 
between methylation of IGF2 and birthweight differed by maternal prenatal vitamin use,  
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but the associations were not significant even after adjusting for confounders.  Among 
infants exposed to prenatal vitamins, one standard deviation increase in methylation of 
IGF2 was associated with a non-significant 0.78% decrease in birthweight (95%CI-4.17, 
2.61). On the other hand, among infants born to women who did not use prenatal 
vitamins, a one standard deviation increase in methylation of IGF2 was associated with 
a 3.72% increase in birthweight (95%CI= -5.32, 12.76). Results from analyses examining 
IGF1 stratified by prenatal vitamin were similar to that of the unstratified analysis. Among 
prenatal vitamin users, a one standard deviation increase in methylation of IGF1 was 
associated with a 4.21% decrease in birthweight (95%CI= -7.44, -0.98). Comparable 
results were found for women who did not use prenatal vitamins, though they were not 
statistically significant (β= -3.71, 95%CI= -11.07, 3.64). In an attempt to increase power 
in the examination of prenatal vitamin use as a moderator of the DNA hypermethylation–
birthweight association, prenatal vitamin use and an interaction term were added to the 
final model for IGF1 and then IGF2. In both cases, the interaction terms were non-
significant [(IGF1=-3.93, 95%CI=-12.72, 4.87); (IGF2=-7.32, 95%CI=-16.95, 2.31)]. 
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Table A.1 Concentration (ng/µl) of DNA extracted from each sample of umbilical cord 
blood derived nucleated cells 
Sample ID 
Concentration 
(ng/µl) 
Sample ID 
(continued) 
Concentration 
(ng/µl) 
Sample ID 
(continued) 
Concentration 
(ng/µl) 
207 36.69 JS032 77.02 JS066 96.78 
210 42.95 JS033 99.86 JS067 113.88 
213 41.98 JS034 0.41 JS068 21.27 
214 42.2 JS035 5.86 JS069 112.04 
215 50.17 JS036 19.11 JS070 3.52 
216 53.87 JS037 19.85 JS071 8.1 
JS007 74.6 JS040 95.79 JS074 9.06 
JS008 46.78 JS041 7.8 JS075 65.26 
JS009 82.7 JS042 9.59 JS076 3.14 
JS010 119.36 JS043 94.05 JS077 81.52 
JS011 21.06 JS044 16.68 JS078 1.58 
JS012 14.39 JS045 82.07 JS079 30.85 
JS013 13.54 JS046 11.1 JS080 1.47 
JS014 12.92 JS047 9.12 JS081 6.66 
JS015 16.75 JS048 53.25 JS082 53.71 
JS016 8.19 JS050 11.53 JS083 69.04 
JS017 66.31 JS051 20.94 JS084 126.35 
JS018 12.75 JS052 26.69 JS085 43.28 
JS019 31.16 JS053 10.42 JS086 3.37 
JS020 92.52 JS054 85.04 JS087 85.1 
JS021 98.21 JS055 3.79 JS088 74.16 
JS022 16.33 JS056 142.1 JS089 66.55 
JS023 24.59 JS057 120.47 JS090 88.74 
JS024 83.12 JS058 102.84 JS091 154.26 
JS025 17.75 JS059 19.36 JS092 118.69 
JS026 39 JS060 40.06 JS093 38.98 
JS027 149.81 JS061 4.33 JS094 3.5 
JS028 118.61 JS062 45.33 JS099 140.47 
JS029 36.54 JS063 114.35 JS100 85.14 
JS030 38.49 JS064 79.45 JS101 107.97 
JS031 8.58 JS065 165.39 blank__93 0 
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Table A.2 Distribution of the mean methylation level of each housekeeping gene by 
gender  
Mean Methylation Level 
Gene Male Female 
EFNB1  0.05 0.39
GLA    0.06 0.25
FMR1   0.19 0.45
GPC3   0.03 0.57
ELK1   0.05 0.55
G6PD   0.05 0.33
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Table A.3 Pearson correlation coefficients for assessment of interchip variability 
 
Sample ID R p-value 
JS020 0.998 <0.0001 
JS052 0.998 <0.0001 
JS079 0.997 <0.0001 
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Table A.4 Distribution of the beta values for the CpG sites assessed in manuscript 1 
 
Gene Mean Standard 
Deviation 
Minimum Maximum 
CYP1A1, CpG site 1 0.02 0.01 0.01 0.04 
CYP1A1, CpG site 2 0.05 0.01 0.03 0.08 
CYP1A1, CpG site 3 0.04 0.03 0.01 0.14 
CYP1A1, CpG site 4 0.19 0.03 0.13 0.25 
HIF1A, CpG site 1 0.04 0.01 0.02 0.10 
HIF1A, CpG site 2 0.03 0.02 0.01 0.17 
GSTM1 0.10 0.10 0.01 0.35 
GSTT1 0.09 0.11 0.02 0.45 
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Table A.5 Summary of the confounders assessed for the association between SGA1 and methylation of selected genes  
 
CYP1A1 HIF1A GSTM1 GSTT1 
Variable 
Variable 
type OR2,3 
%  
Change4  OR 
% 
change  OR % change OR 
% 
change  
crude association   0.868   1.232   0.972   1.077   
                    
Gender categorical 0.985 13.48 1.428 15.91 0.984 1.23 1.087 0.93
Parity categorical 0.894 3.00 1.206 -2.11 0.964 -0.82 1.091 1.30
Smoker categorical 0.836 -3.69 1.247 1.22 0.973 0.10 1.076 -0.09
Smoke exposure (cotinine 
level) continuous 0.814 -6.22 1.241 0.73 0.976 0.41 1.069 -0.74
Prenatal vitamin use categorical 0.870 0.23 1.241 0.73 0.972 0.00 1.079 0.19
Pregnancy complications categorical 0.893 2.88 1.223 -0.73 0.973 0.10 1.077 0.00
Maternal age continuous 0.889 2.42 1.231 -0.08 0.975 0.31 1.102 2.32
Prenatal care categorical 0.877 1.04 1.184 -3.90 0.980 0.82 1.086 0.84
Race-white, black, other categorical 0.873 0.58 1.213 -1.54 0.992 2.06 1.071 -0.56
Race-black, non-black categorical 0.868 0.00 1.219 -1.06 0.994 2.26 1.073 -0.37
1SGA=small for gestational age 
2OR=Odds ratio 
3Odds ratios for a 0.01 increase in methylation level  
4the percent change in the odds ratio from the crude odds ratio attributed to the addition of the selected variable  
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Table A.6 Parameter estimates and model fit statistics for the crude and adjusted models assessing the association between 
methylation of selected genes and SGA 
Hosmer and 
Lemeshow 
Goodness-of-fit test 
Model fit statistics 
for the intercept and 
covariates 
Variable 
Parameter 
Estimate 
Standard 
Error 
Wald              
Chi-Square 
pr> 
Chi-square 
Chi-
square p-value 
AIC -2 Log L 
CYP1A1 4.50 0.81 66.56 62.56
Intercept -1.03 2.18 0.22 0.64
CYP1A1      -14.10 29.43 0.23 0.63
CYP1A1 2.43 0.97 55.76 39.76
Intercept  -0.46 3.63 0.02 0.90
CYP1A1      -3.29 43.96 0.01 0.94
Gender -3.06 1.31 5.47 0.02
Maternal Age -0.06 0.09 0.45 0.50
Parity 1.07 0.94 1.30 0.25
Cotinine 0.03 0.02 2.35 0.13
Prenatal Care -0.56 0.94 0.35 0.55
Race 2.12 0.97 4.79 0.03
HIF1A 13.70 0.09 65.46 61.46
Intercept  -2.86 0.75 14.48 <0.01
HIF1A      20.85 17.12 1.48 0.22
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Table A.6 (Continued) Parameter estimates and model fit statistics for the crude and adjusted models assessing the association 
between methylation of selected genes and SGA  
Hosmer and 
Lemeshow 
Goodness-of-fit test 
Model fit statistics 
for the intercept and 
covariates 
Variable 
Parameter 
Estimate 
Standard 
Error 
Wald              
Chi-Square 
pr> 
Chi-square 
Chi-
square p-value 
AIC -2 Log L 
HIF1A 4.77 0.78 52.23 36.23
 Intercept  -1.22 2.85 0.18 0.67
 HIF1A      46.50 24.18 3.70 0.05
 Gender -4.02 1.67 5.83 0.02
 Maternal Age -0.10 0.10 1.02 0.31
 Parity 0.99 1.01 0.96 0.33
 Cotinine 0.04 0.02 2.67 0.10
 Prenatal Care -0.44 0.93 0.22 0.64
 Race 2.10 1.00 4.39 0.04
GSTM1  1.99 0.98 66.18 62.18
 Intercept  -1.82 0.46 15.96 <0.01
 GSTM1       -2.83 3.78 0.56 0.46
GSTM1  3.83 0.87 63.63 49.63
 Intercept  -1.40 2.33 0.36 0.55
 GSTM1       0.48 4.24 0.01 0.91     
 Maternal Age -0.05 0.08 0.44 0.51     
 Parity 0.97 0.89 1.19 0.27     
 Cotinine 0.02 0.02 1.17 0.28     
 Prenatal Care -0.97 0.79 1.50 0.22     
 Race 2.02 0.84 5.73 0.02     
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Table A.6 (Continued) Parameter estimates and model fit statistics for the crude and adjusted models assessing the association 
between methylation of selected genes and SGA  
Hosmer and 
Lemeshow 
Goodness-of-fit test 
Model fit statistics 
for the intercept and 
covariates 
Variable 
Parameter 
Estimate 
Standard 
Error 
Wald              
Chi-Square 
pr> 
Chi-square 
Chi-
square p-value 
AIC -2 Log L 
GSTT1 15.78 0.05 57.71 53.71
 Intercept  -3.05 0.55 30.61 <0.01
 GSTM1  7.41 2.44 9.20 <0.01
GSTT1  8.22 0.41 54.34 40.34
 Intercept  -0.50 2.89 0.03 0.86     
 GSTM1       9.91 3.58 7.66 0.01     
 Maternal Age -0.12 0.10 1.46 0.23     
 Parity 1.38 1.05 1.73 0.19     
 Cotinine 0.00 0.02 0.02 0.88     
 Prenatal Care -1.28 0.92 1.94 0.16     
 Race 1.64 0.91 3.23 0.07     
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Table A.7 Summary of the confounders assessed for the association between methylation of selected genes and cigarette smoke 
exposure  
GSTT1 GSTM1 HIF1A CYP1A1 
Variable 
variable 
type OR1,2 
% 
change3 OR 
% 
change OR 
% 
change OR 
% 
change 
crude   1.030   0.985   1.010   0.998   
                    
Gender categorical 1.031 0.10 0.984 -0.10 1.011 0.10 0.997 -0.10
Parity categorical 1.030 0.00 0.984 -0.10 1.011 0.10 1.000 0.20
Prenatal vitamin use categorical 1.029 -0.10 0.982 -0.30 1.007 -0.30 0.995 -0.30
Pregnancy complications categorical 1.030 0.00 0.985 0.00 1.011 0.10 0.998 0.00
Maternal age continuous 1.031 0.10 0.989 0.41 1.015 0.50 0.999 0.10
prenatal care categorical 1.032 0.19 0.986 0.10 1.011 0.10 0.998 0.00
Race-white, black, other categorical 1.032 0.19 0.983 -0.20 1.005 -0.50 0.992 -0.60
Race-black, non-black categorical 1.031 0.10 0.986 0.10 1.011 0.10 0.998 0.00
Gestational age continuous 1.032 0.19 0.987 0.20 1.010 0.00 0.997 -0.10
1OR=odds ratio 
2The odds ratio is for a 1 ng/ml increase in cotinine level 
3the percent change in the odds ratio from the crude odds ratio attributed to the addition of the selected variable  
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Table A.8 Parameter estimates and model fit statistics for the crude and adjusted models assessing the association between 
smoking and hypermethylation of selected genes 
Hosmer and 
Lemeshow 
Goodness-of-fit 
test 
Model fit statistics 
for the intercept 
and covariates 
Variable 
Parameter 
Estimate 
Standard 
Error 
Wald              
Chi-Square 
pr> 
Chi-square 
Chi-
square p-value 
AIC -2 Log L 
Hypermethylation 
of CYP1A1 3.13 0.08 104.09 100.09
Intercept   -1.12 0.25 19.41 <0.01 
Cotinine -0.002 0.02 0.02 0.89 
Hypermethylation 
of CYP1A1 7.78 0.46 107.60 99.60
Intercept   -1.28 1.22 1.11 0.29 
Cotinine 0.00 0.02 0.01 0.94 
Maternal Age 0.01 0.04 0.04 0.83 
Race -0.37 0.64 0.34 0.56 
Hypermethylation 
of HIF1A 0.08 . 105.73 101.73
Intercept   -1.12 0.25 19.55 <0.01 
Cotinine 0.01 0.01 0.60 0.44 
Hypermethylation 
of HIF1A 8.84 0.26 106.96 98.96
Intercept   -3.15 1.29 5.93 0.01 
Cotinine 0.02 0.01 1.23 0.27   
Maternal Age 0.07 0.04 2.58 0.11   
Race 0.46 0.60 0.61 0.44   
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Table A.8 (Continued) Parameter estimates and model fit statistics for the crude and adjusted models assessing the association 
between smoking and hypermethylation of selected genes 
Hosmer and 
Lemeshow 
Goodness-of-fit 
test 
Model fit statistics 
for the intercept 
and covariates 
Variable 
Parameter 
Estimate 
Standard 
Error 
Wald              
Chi-Square 
pr> 
Chi-square 
Chi-
square p-value 
AIC -2 Log L 
Hypermethylation 
of GSTM1 0.90 0.34 105.65 101.65
 Intercept   -1.02 0.25 16.77 <0.01 
 Cotinine -0.01 0.02 0.52 0.47 
Hypermethylation 
of GSTM1   8.81 0.29 106.75 98.75
 Intercept   -1.98 1.22 2.64 0.10 
 Cotinine -0.01 0.02 0.31 0.58 
 Maternal Age 0.04 0.04 0.93 0.34 
 Race -0.74 0.70 1.11 0.29 
Hypermethylation 
of GSTT1   0.01 . 101.78 97.78
 Intercept   -1.23 0.26 22.17 <0.01 
 Cotinine 0.03 0.02 3.89 0.05 
Hypermethylation 
of GSTT1   10.20 0.18 100.88 92.88
 Intercept   -2.72 1.35 4.02 0.05 
 Cotinine 0.03 0.02 4.67 0.03 
 Maternal Age 0.04 0.04 0.82 0.37 
 Race 1.29 0.59 4.77 0.03 
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Table A.9 Summary of the confounders assessed for the association between methylation of IGF1 and IGF2 and birthweight  
 
IGF1 IGF2 
Variable Variable type β1 p-value2 β p-value 
Crude   -0.041   -0.006 0.81
          
Gender categorical -0.049 <0.01 -0.019 <0.01
Parity categorical -0.043 <0.01 -0.004 <0.01
Smoker categorical -0.041 0.54 -0.006 0.58
Smoke exposure (cotinine level) continuous -0.041 0.37 -0.004 0.39
Prenatal vitamin use categorical -0.040 0.89 -0.006 0.79
Pregnancy complications categorical -0.041 0.02 -0.008 0.03
Maternal age continuous -0.045 0.01 -0.009 0.02
Gestational age continuous -0.029 <0.01 0.007 <0.01
Preterm categorical -0.032 <0.01 -0.415 <0.01
Prenatal care categorical -0.038 0.17 -0.006 0.14
Race-white, black, other categorical -0.039 0.59, 0.70 -0.005 0.46, 0.79
Race-black, non-black categorical -0.038 0.70 -0.006 0.47
1 Betas (β) are for the association of interest and represent the change in log(birthweight) for a one standard deviation increase in 
methylation 
2p-value represents the significance of the covariate added to the univariate model 
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Table A.10 Summary of the parameter estimates and fit statistics for the crude and 
adjusted models examining the association between methylation of IGF1, IGF2, and the 
CpG sites in IGF2 and birthweight 
Variable 
Parameter 
Estimate 
Standard 
Error t-value pr>|t| R sq 
IGF1 
Intercept 8.059 0.025 318.200 <0.0001 0.028
Z-score of 
methylation of IGF1 -0.041 0.025 -1.590 0.115 
IGF1 0.716
Intercept 5.044 0.278 18.130  <.0001 
Z-score of 
methylation of IGF1 -0.036 0.014 -2.530 0.013 
Gender 0.088 0.030 2.950 0.004 
Maternal Age 0.003 0.002 1.430 0.158 
Parity -0.084 0.032 -2.600 0.011 
Gestational Age 0.076 0.007 10.540  <.0001 
Complications 0.008 0.033 0.230 0.820 
IGF2 0.001
Intercept 8.059 0.026 313.830 <.0001 
Z-score of 
methylation of IGF2 -0.006 0.026 -0.240 0.811 
IGF2 0.694
Intercept 4.984 0.289 17.240  <.0001 
Z-score of 
methylation of IGF2 0.001 0.015 0.050 0.964 
Gender 0.080 0.031 2.580 0.012 
Maternal Age 0.003 0.002 1.190 0.239 
Parity -0.083 0.033 -2.470 0.016 
Gestational Age 0.078 0.007 10.410  <.0001 
Complications 0.012 0.034 0.340 0.738 
IGF2, CpG site 1 0.0002
Intercept 8.059 0.026 313.750 <.0001 
Z-score of 
methylation of IGF2, 
CpG site 1 -0.003 0.026 0.905 -0.054 
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Table A.10 (Continued) Summary of the parameter estimates and fit statistics for the 
crude and adjusted models examining the association between methylation of IGF1, 
IGF2, and the CpG sites in IGF2 and birthweight 
Variable 
Parameter 
Estimate 
Standard 
Error t-value pr>|t| R sq 
IGF2, CpG site 1 0.694
Intercept 4.984 0.288 17.310  <.0001 
Z-score of 
methylation of IGF2, 
CpG site 1 -0.001 0.015 -0.080 0.940 
Gender 0.081 0.031 2.620 0.010 
Maternal Age 0.003 0.002 1.190 0.236 
Parity -0.083 0.034 -2.470 0.016 
Gestational Age 0.078 0.007 10.480  <.0001 
Complications 0.012 0.035 0.340 0.735 
IGF2, CpG site 2 0.0001
Intercept 8.059 0.026 313.740 <0.0001 
Z-score of 
methylation of IGF2, 
CpG site 2 -0.002 0.026 -0.090 0.928 
IGF2, CpG site 2 0.694
Intercept 4.982 0.290 17.210  <.0001 
Z-score of 
methylation of IGF2, 
CpG site 2 0.001 0.015 0.100 0.922 
Gender 0.080 0.031 2.570 0.012 
Maternal Age 0.003 0.002 1.190 0.238 
Parity -0.083 0.033 -2.470 0.015 
Gestational Age 0.078 0.007 10.410  <.0001 
Complications 0.012 0.035 0.340 0.733 
IGF2, CpG site 3 0.044
Intercept 8.059 0.025 320.900 <.0001 
Z-score of 
methylation of IGF2, 
CpG site 3 -0.051 0.025 -2.020 0.047 
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Table A.10 (Continued) Summary of the parameter estimates and fit statistics for the 
crude and adjusted models examining the association between methylation of IGF1, 
IGF2, and the CpG sites in IGF2 and birthweight 
Variable 
Parameter 
Estimate 
Standard 
Error t-value pr>|t| R sq 
IGF2, CpG site 3 0.699
Intercept 5.037 0.288 17.460  <.0001 
Z-score of 
methylation of IGF2, 
CpG site 3 -0.018 0.015 -1.210 0.228 
Gender 0.083 0.031 2.730 0.008 
Maternal Age 0.003 0.002 1.190 0.238 
Parity -0.077 0.033 -2.310 0.024 
Gestational Age 0.076 0.007 10.260  <.0001 
Complications 0.008 0.034 0.240 0.807 
IGF2, CpG site 4 0.001
Intercept 8.059 0.026 313.810 <.0001 
Z-score of 
methylation of IGF2, 
CpG site 4 -0.005 0.026 -0.210 0.835 
IGF2, CpG site 4 0.699
Intercept 4.982 0.285 17.450  <.0001 
Z-score of 
methylation of IGF2, 
CpG site 4 -0.017 0.015 -1.150 0.252 
Gender 0.079 0.031 2.580 0.012 
Maternal Age 0.003 0.002 1.340 0.183 
Parity -0.086 0.033 -2.580 0.012 
Gestational Age 0.078 0.007 10.540  <.0001 
Complications 0.009 0.034 0.260 0.795 
IGF2, CpG site 5 0.0003
Intercept 8.059 0.026 313.770 <.0001 
Z-score of 
methylation of IGF2, 
CpG site 5 0.004 0.026 0.150 0.880 
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Table A.10 (Continued) Summary of the parameter estimates and fit statistics for the 
crude and adjusted models examining the association between methylation of IGF1, 
IGF2, and the CpG sites in IGF2 and birthweight 
Variable 
Parameter 
Estimate 
Standard 
Error t-value pr>|t| R sq 
IGF2, CpG site 5 0.697
Intercept 4.962 0.288 17.230  <.0001 
Z-score of 
methylation of IGF2, 
CpG site 5 0.012 0.015 0.840 0.406 
Gender 0.077 0.031 2.470 0.016 
Maternal Age 0.003 0.002 1.230 0.224 
Parity -0.084 0.033 -2.520 0.014 
Gestational Age 0.078 0.007 10.550  <.0001 
Complications 0.014 0.034 0.400 0.691 
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Table A.11 Association between birthweight and DNA methylation of IGF1, IGF2, and 
the CpG sites in IGF2 after adding race as a covariate 
 Β1, 2 95% CI3 
IGF1 -3.12 -6.09, -0.15 
IGF2 0.26 -2.69, 3.21 
 CpG site 1 -0.04 -2.98, 2.89 
 CpG site 2 0.16 -2.79, 3.11 
 CpG site 3 -1.45 -4.44, 1.53 
 CpG site 4 -1.88 -4.79, 1.03 
  CpG site 5 1.62 -1.33, 4.56 
1Percent change in birthweight per standard deviation change in methylation level 
2Adjusted for gender, maternal age, parity, gestational age, pregnancy complications, 
and race 
3CI=confidence interval
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Figure A.1 Plot of birthweight verses the z-score transformed methylation values for the 
IGF2 gene 
 
  
0
1000
2000
3000
4000
5000
6000
-4 -3 -2 -1 0 1 2 3 4
bi
rt
hw
ei
gh
t (
gr
am
s)
z-score
Birthweight versus z-score transformed 
methylation levels of the IGF2 gene
104 
 
APPENDIX A (CONTINUED) 
 
 
Figure A.2 Plot of birthweight verses the z-score transformed methylation values for the 
IGF1 gene 
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For manuscript 1, the logistic statement in proc power (SAS 9.2) was used to 
perform the power analysis. For the analyses examining the association between SGA 
and DNA methylation of CYP1A1, HIF1a, GSTM1, or GSTT1, the distribution of the 
predictor of interest, DNA methylation, was specified for each gene, alpha was kept at 
0.05, and the sample size was fixed at 90. Power was calculated for several different 
odds ratios (1.1, 1.5, 2.0, and 2.5) using a response probability of 0.11. Table C.1 
provides an overview of the results from the power calculations. GSTT1 and GSTM1 had 
greater than 80% power for all the odds ratios examined. The study was underpowered 
to detect small changes in the odds ratio for CYP1A1 and HIF1A, but had greater than 
90% power for larger odds ratios (i.e. odds ratios of 2.5). Manuscript one also sought to 
examine the association between cotinine level and DNA hypermethylation (outcome). 
For this power analysis, alpha was set at 0.05, response probability was 0.25, the 
sample size was fixed at 90, and the distribution of the cotinine variable was specified. 
Power was the same for all the genes (>99%) and is summarized in Table C.1. 
 For manuscript 2, the power analysis was done using the multreg statement in 
proc power (SAS 9.2). Alpha was fixed at 0.05, the sample size was 90 and the R-
square of the full model as well as the change in R-square were specified for both IGF1 
and IGF2. While there was sufficient power for IGF1 (86.6%), analyses of IGF2 lacked 
power (7.3%). 
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Table C.1. Summary of power analysis for Manuscript 1 
 
 Power  
SGA and methylation of each gene OR=1.1 OR=1.5 OR=2.0 OR=2.5 
 CYP1A1 6.2% 28.3% 68.7% 91.3% 
 HIF1A 6.8% 41.7% 87.7% 98.8% 
 GSTM1 81.0% >99.9% >99.9% >99.9% 
 GSTT1 88.3% >99.9% >99.9% >99.9% 
Hypermethylation of each gene and 
cotinine level 
>99.9% >99.9% >99.9% >99.9% 
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